absorbent article

专利摘要:
ABSORBENT ARTICLE. An object of the present invention is to provide an absorbent article without a sticky sensation on the topsheet and with a smooth topsheet, even after high viscosity menstrual blood has been absorbed. The absorbent article of the present invention is as follows. An absorbent article comprising a liquid-permeable topsheet, a liquid-impermeable backsheet, and an absorbent body between the liquid-permeable topsheet and a liquid-impermeable backsheet, characterized in that the liquid-permeable topsheet comprises a blood with an IOB of 0.00-0.60, a melting point of not more than 45 ° C, a water solubility of 0.000.05 g in 100 g of water at 25 ° C, and an average molecular weight of not more than 1,000 .
公开号:BR112013024052B1
申请号:R112013024052-0
申请日:2012-03-23
公开日:2021-03-09
发明作者:Shimpei Komatsu；Yuki Noda；Mitsuhiro Wada；Akira Hashino；Hideyuki Kinoshita；Masashi Nakashita；Ichiro Wada
申请人:Unicharm Corporation；
IPC主号:

专利说明:

[0001] The present description refers to an absorbent article. TECHNICAL STATUS
[0002] As the basic performance of absorbent articles, such as sanitary napkins and panties linings, has continued to improve with technological developments over many years, the leak after the absorption of waste, such as, menstrual blood has become a less frequent occurrence than in the past. Recent developments are now geared towards absorbent articles with an even higher performance, including a sensation similar to underwear, and the smoothness of the top sheet, even after the absorption of waste, such as menstrual blood. Menstrual blood during menstruation, in particular, may also contain endometrial components, which are highly viscous, and the topsheet must be smooth and stem-free, even after absorption of menstrual blood as highly viscous. Highly viscous menstrual blood usually remains on the top sheet in the form of masses, in general, leaving the user with a visually unpleasant image and therefore from this point of view it is also preferable that the menstrual blood is not highly viscous to remain on the top sheet.
[0003] LPL 1, for example, describes an absorbent article that includes cellulose-based hydrophilic fiber that comprises one or more surfactants selected from the group consisting of alkyl ethers and fatty acid sugar esters in positions other than contact with the skin surface.
[0004] In addition, LPT 2 describes an absorbent article that has a polypropylene glycol material containing a lotion composition on the inner surface of the top sheet (side surface of the garment), the inner surface of the back sheet (side surface of the body), and not the base material between the inner surface of the top sheet and the inner inner surface of the sheet.
[0005] In addition, PLT 3 describes an absorbent article in which a lotion composition for the material containing polypropylene glycol is applied to the outer surface of the top sheet (side surface of the body). Citation list PLT patent literature 1 Unexamined Japanese Patent Publication No. 2008-029830 PLT 2 Unexamined Japanese Patent Publication No. 2010-518918 PLT 3 WO2009 / 102837 Summary of the Invention Technical problem
[0006] According to a PLT 1, however, the inventors noted that an attempt was made to use a "surfactant" to alter the viscosity and surface tension of highly viscous menstrual blood and increase the rate of liquid absorption, but the effect may not be suitable, and it may not be possible to get a smooth sensation on the top sheet without a sticky sensation after the highly viscous menstrual blood has been absorbed. In addition, according to LPT 1, it may be necessary to coat the surfactant as an aqueous solution, and therefore problems from the point of view of productivity may arise when a subsequent drying step is included.
[0007] When the present inventors confirmed the effects of that described in PTLs 2 and 3, it was found that the polypropylene glycol material has different absorptive power, depending on its molecular weight, and that, with the low weight polypropylene glycol materials molecular, a sticky sensation remains and the redness of the blood tends to remain on the top sheet after blood absorption. It has also been found that, with high molecular weight polypropylene glycol materials, the adhesion of the material tends to result in a sticky sensation.
[0008] Therefore, it is an object of the present invention to provide an absorbent article, without a sticky sensation on the topsheet, and with a smooth topsheet, even after the highly viscous menstrual blood has been absorbed.
[0009] It is another object of the invention to provide an absorbent article which is resistant to the residue of highly viscous menstrual blood on the topsheet, and which does not tend to leave the user with a visually unpleasant image. Solution to the problem
[0010] As a result of diligent research aimed at solving the problems described above, the present inventors have found that the problems can be solved by an absorbent article comprising a liquid-permeable topsheet, a liquid-impermeable backsheet and an absorbent body between the liquid-permeable topsheet and the liquid-impermeable backsheet, wherein the liquid-permeable topsheet comprises a blood modifying agent with an IOB of 0.00-0.60, a melting point not exceeding 45 ° C , a water solubility of 0.00-0.05 g in 100 g of water at 25 ° C, and an average molecular weight of less than 1,000. Advantageous Effects of Invention
[0011] The absorbent article of the invention allows menstrual blood to migrate quickly from the upper sheet to the absorbent body, and thus highly viscous menstrual blood does not easily remain on the top sheet, and the top sheet having a smooth sensation without being sticky.
[0012] The absorbent article according to the invention is resistant to highly viscous menstrual blood masses remaining on the top sheet, and does not tend to leave the user with a visually unpleasant image.
[0013] For a better understanding of the invention, detailed reference will be made to it, with respect to the attached drawings, presented in an exemplary and non-limiting character, in which: - FIG. 1 is a plan view of Example 1, showing the region of the superposed sheet containing the blood modifying agent; - FIG. 2 is an electron micrograph of the surface in contact with the skin of a topsheet in a sanitary pad, where the topsheet comprises C2L oil tri-glycerides of fatty acids; FIG. 3 is a pair of photomicrographs of menstrual blood containing and not containing a blood modifying agent; - FIG. 4 is a diagram illustrating a method of measuring surface tension. Description of settings
[0014] The absorbent article of the present description will now be explained in detail [Blood modifying agent]
The blood modifying agent of this invention has an IOB of about 0.00-0.60, a melting point of no more than about 45 ° C, a water solubility of about 0.00- 0.05 g to 25 ° C, and an average molecular weight by weight of less than about 1,000.
[0016] IOB (Inorganic organic balance) is an indicator of hydrophilic-lipophilic balance, and as used here, it is the value calculated by the following formula by Oda et al .: IOB = inorganic value / organic value.
[0017] The inorganic and organic value are based on the organic paradigm described in "organic composite predictions and organic paradigms" by A. Fujita, Kagaku no Rioiki (Japanese Journal of Chemistri), Vol.11, No. 10 (1957) p. 719-725, which is incorporated herein by reference.
[0018] The organic and inorganic values of the large group values, according to Fujita, are summarized in Table 1 below. Table 1

[0019] For example, in the case of a tetradecanoic acid ester that has 14 carbon atoms and dodecyl alcohol that has 12 carbon atoms, the organic value is 520 (CH2, 20 x 26) and the inorganic value is 60 (- COOR, 60 x 1), and therefore IOB = 0.12.
[0020] In the blood modifying agent, the IOB is about 0.00 0.60, preferably about 0-0.50, more preferably about 0-0.40 and even more preferably about 0-0, 30. This is because a lower IOB is associated with greater organism and greater affinity with blood cells.
[0021] As used herein, the term "melting point" refers to a peak temperature for the endothermic peak during conversion from solid to liquid, by measuring with a differential scanning calorimetry analyzer at a rate of temperature rise of 10 ° C / min. The melting point can be measured using a DSC-60 DSC measuring device by the Shimadzu Corp model, for example.
[0022] If the blood-modifying agent has a point of no more than about 45 ° C, it can be liquid or solid at room temperature, or, in other words of melting, the melting point can be any one of about 25 ° C or higher, or less than about 25 ° C, and for example, it can have a melting point of about -5 ° C or about -20 ° C. The reason for a point of no more than about 45 ° C for the blood fusion modifying agent will be explained below.
[0023] The blood modifying agent does not have a lower limit for the melting point, but the vapor pressure is preferably low. The vapor pressure of the modifying agent is preferably about 0.00-0.01 Pa, more preferably about 0.000-0.001 Pa and even more preferably about 0.0000-0.0001 Pa, at 1 atmosphere and at 25 ° C.
[0024] Considering that the absorbent article of the present description is to be used in contact with the human body, the vapor pressure is preferably about 0.00-0.01 Pa, more preferably about 0.000-0.001 Pa and even more preferably about 0.0000-0.0001 Pa, in an atmosphere, at 40 ° C.
[0025] If the vapor pressure is high, gasification can occur during storage and the amount of modifying agent in the blood can be reduced, and can create problems, such as, odor during wear.
[0026] The melting point of the blood modifying agent may be different, depending on the time or the duration of the garment. For example, in areas with a significant atmosphere of no more than about 10 ° C, using a blood modifying agent with a point of no greater than about 10 ° C, may allow the modifying agent to modify the blood of stable in the blood after excretion of menstrual blood, even if it has been cooled by melting at room temperature.
[0027] In addition, when the absorbent article is used for an extended period of time, the melting point of the blood modifying agent is preferably at the highest end of the range of no more than about 45 ° C.
[0028] This is because the blood modifying agent is not easily affected by sweat or friction while wearing the garment and will not be easily migrated, even during prolonged use.
[0029] The solubility of 0.00-0.05 g of water can be measured by adding 0.05 g of sample to 100 g of deionized water at 25 ° C, allowing to stand for 24 hours, and gently stirring if necessary, and then visually assess whether or not the sample has dissolved.
[0030] As used herein, the term "solubility" with respect to water solubility includes cases where the sample completely dissolves in deionized water to form a homogeneous mixture and, in cases where the sample is completely emulsified. As used herein, "completely" means that no mass of the sample remains in the deionized water.
[0031] In the technique described above, the surfaces of the upper sheets are coated with surfactants, in order to alter the surface tension of the blood and promote the rapid absorption of blood. However, because surfactants generally have greater solubility in water, the surfactant-coated topsheet is highly miscible with hydrophilic components (such as blood plasma) in the blood, and therefore, instead, they tend to cause blood on the top sheet. The aforementioned blood modifying agent has low water solubility and, therefore, unlike the surfactants used in the art described above, it does not cause blood residue on the topsheet and allows rapid migration into the absorbent body.
[0032] As used herein, water solubility in 100 g of water at 25 ° C can be simply referred to as "water solubility".
[0033] The blood modifying agent can have water solubility of about 0.00 g. Therefore, the lower limit for blood-modifying agent water solubility is approximately 0.00 g.
[0034] The blood modifying agent has an average molecular weight by weight of less than about 1,000 and, preferably, an average molecular weight by weight of less than about 900. This is because, if the average molecular weight in weight is about 1,000 or more, it can result in the adherence of the blood-modifying agent itself, tending to create a feeling of dislike for the user. In addition, a high average molecular weight by weight tends to result in higher viscosity of the blood modifying agent, and it will be difficult to decrease the viscosity of the blood modifying agent by heating, to a viscosity suitable for the coating. As a result, it will sometimes be necessary to dilute the blood modifying agent with a solvent.
The blood modifying agent preferably has a weight average molecular weight of about 100 or more, and more preferably has a weight average molecular weight of about 200 or more. This is because, if the average molecular weight by weight is low, the vapor pressure can be increased, gasification can occur during storage and the amount of modifying agent in the blood can be reduced, and can create problems, such as, the odor while wearing the garment.
[0036] As used herein, "average molecular weight" includes the concept of a polydispersed compound (for example, a compound produced by step polymerization, an ester formed from a plurality of fatty acids and a plurality of alcohols aliphatic), and a simple compound (for example, an ester formed from a fatty acid and an aliphatic monohydric alcohol), and, a system comprising molecules with a molecular weight of Ni Mi (i = 1, or i = 1, 2 ...), refers to MW determined by the following formula. Mw = ∑NiMi 2 / ∑NiMi
[0037] As used herein, the average molecular weight weights are the values measured by gel permeation chromatography (GPC), based on polystyrene.
[0038] The GPC measurement conditions can be as follows, for example.
[0039] Device: LaChrom High Speed Elite Liquid Chromatogram by Hitachi High-Technologies Corp
[0040] Speakers: Shodex KF-801, KF-803 and KF-804, by Showa Denko KK
[0041] Eluent: THF
[0042] Flow Rate: 1.0 mL / min
[0043] Targeting volume: 100 μ]
[0044] Detection: IR (differential refractometer)
[0045] The average molecular weights by weight indicated in the examples of the present specification were measured under the conditions described below.
[0046] Preferably, blood modifying agents are selected from the group consisting of the following items: (i) - (iii), and any combination thereof: (i) a hydrocarbon; (ii) a compound that has (ii-1) a hydrocarbon fraction, and (ii-2) one or more groups, the same or different, selected from the group consisting of a carbonyl group (-CO-) and a group oxy (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii) a compound that has (iii-1) a hydrocarbon radical, (iii-2) one or more identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii-3) one or more groups, the same or different, selected from among group consisting of carboxyl groups (-COOH) and a hydroxyl group (-OH), replacing a hydrogen atom of the hydrocarbon portion.
[0047] As used herein, "hydrocarbon" refers to a compound consisting of carbon and hydrogen, and may be a hydrocarbon and chain, such as a paraffinic hydrocarbon (Not containing any double or triple bond, also referred to as alkane), an olefin-based hydrocarbon (containing a double bond, also known as an alkene), an acetylene-based hydrocarbon (containing a triple bond, also referred to as an alkaline), or a hydrocarbon comprising two or more bonds selected from the group consisting of double bonds and triple bonds, and cyclic hydrocarbons, such as aromatic hydrocarbons and alicyclic hydrocarbons.
[0048] It is preferable that these hydrocarbons are chain hydrocarbons and hydrocarbons are alicyclic, chain hydrocarbons being more preferred, paraffinic hydrocarbons hydrocarbons and hydrocarbons having two or more double bonds (not containing any triple bond), being more preferred, and hydrocarbons paraffinic, being even more preferred based on olefin.
[0049] Straight chain hydrocarbons include hydrocarbons and branched hydrocarbons.
[0050] When two or more oxy groups (-0-) are inserted in the compounds of (ii) and (iii) above, the oxy groups (-0-) are not adjacent to each other. Thus, compounds (ii), and (iii) do not include compounds with continuous oxy groups (i.e., peroxides).
[0051] In compounds (iii), compounds in which at least one hydrogen in the hydrocarbon radical being replaced with a hydroxyl group (-OH) are more preferred than compounds in which at least one hydrogen in the hydrocarbon radical is replaced with a carboxyl group (- COOH). As shown in Table 1, the metal-bound carboxyl groups and the like, menstrual blood, dramatically increasing the inorganic value from 150 to 400 or higher, and therefore a blood modifying agent with the carboxyl groups that can increase the IOB value more than about 0.60 during use, potentially decreasing affinity with blood cells.
[0052] More preferably, the blood modifying agent is selected from the group consisting of the following items: (i ') - (iii') and any combination thereof: (i ') a hydrocarbon; (ii ') a compound having (ii'-1), a hydrocarbon radical, and (ii'-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (-CO-) , bonding ester (-COO-), bonding carbonate (-OCOO-) and ether bonding (-0-) inserted between a single CC bond of the hydrocarbon fraction, and (iii-1) a compound having (iii'- 1), a hydrocarbon radical, (iii'-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (CO-), ester bond (-COO-), carbonate bond ( -OCOO-), and ether bond (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii'-3) one or more identical or different groups selected from the group consisting of the carboxyl group (-COOH ) and a hydroxyl group (-OH) replacing a hydrogen atom in the hydrocarbon radical.
[0053] When two or more equal or different bonds are introduced into the compound of (ii 1) or (iii '), that is, when two or more bonds, each selected from the group consisting of carbonyl bonds (CO -), ester bonds (-C00-), carbonate bonds (-OCOO-) and ether bonds (-0 - is inserted), the bonds are not adjacent to each other, and at least one carbon atom is located between each of the connections.
[0054] The blood modifying agent is most preferably a compound with no more than about 1.8 carbonyl (-CO-) bonds, no more than 2 ester (-COO-) bonds, no more than about of 1.5 carbonate bonds (-OCOO-), no more than about 6 ether bonds (-0-), no more than about 0.8 carboxyl groups (-COOH) and / or no more than about 1.2 hydroxyl groups (-OH), for every 10 carbon atoms in the hydrocarbon portion.
[0055] Even more preferably, the blood modifying agent is selected from the group consisting of the following items (A) - (F), and any combination thereof: (A) an ester of (A1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical, and (A2), a compound having a chain hydrocarbon radical and a carboxyl group replacing a hydrogen atom on the hydrocarbon fraction of jail; (B) an ether of (B1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (B2), a compound having a chain hydrocarbon radical and a group hydroxyl, replacing a hydrogen atom in the radical hydrocarbon chain; (C) an ester of (C1) of a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a hydrocarbon radical chain and 2-4 carboxyl groups, replacing hydrogen atoms in the hydrocarbon radical and (C2), a compound having a chain hydrocarbon radical and a hydroxyl group, replacing a hydrogen atom in the chain hydrocarbon radical; (D) a compound having a chain hydrocarbon radical and a bond selected from the group consisting of an ether bond (-0-), the carbonyl bond (-CO-), ester bond (-COO-) and bonding carbonate (-0C00-) inserted between a single DC connection of the chain hydrocarbon unit; (E), a polyoxy-C3-C6 alkylene glycol, or alkyl ester or alkyl ether, and (F) a chain hydrocarbon.
[0056] The blood modifying agent in accordance with (A) to (F) will now be described in detail. [(A) Ester of (A1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical, and (A2), a compound having a chain hydrocarbon radical and a carboxyl group replacing a hydrogen atom in the chain hydrocarbon radical].
[0057] Ester (A) (A1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical, and (A2), a compound having a chain hydrocarbon radical and a carboxyl group replacing a hydrogen atom on the chain hydrocarbon radical (hereinafter also referred to as "compound (A)") it is not necessary for all esterified hydroxyl groups to be as long as the IOB, melting point and solubility at water are within the aforementioned ranges.
[0058] Examples of (A1), a compound having a hydrocarbon group chain and 2-4 hydroxyl groups replace hydrogens in the hydrocarbon chain radical (hereinafter also referred to as "compound (A1)") include hydrocarbon chain tetraols such as, namely, alkanetetraols, pentaerythritol, triols, such as chain hydrocarbons, alkanetriols, including glycerins, and diols, such as alkanediol chain hydrocarbons, including glycols.
[0059] Examples of (A2), a compound having a chain hydrocarbon group and a carboxyl group replacing a hydrogen atom in the chain hydrocarbon radical (hereinafter also referred to as "compound (A2)") include compounds in which a hydrogen in the hydrocarbon is replaced with a carboxyl group (-COOH), such as fatty acids.
[0060] Examples for compound (A) include (a1) an ester of a tetraol chain hydrocarbon and at least one fatty acid, (a2) an ester of a chain hydrocarbon triol and at least one fatty acid, and ( a3) an ester of a diol chain hydrocarbon and at least one of fatty acids. [(a1) of a tetraol chain hydrocarbon ester and at least one fatty acid]
[0061] Examples of an ester of a tetraol chain hydrocarbon and at least one fatty acid include tetraesters of pentaerythritol and fatty acids, represented by the following general formula (1):

[0062] fatty acid and pentaerythritol triesters, represented by the following formula (2):

[0063] 1 diesters of fatty acids and pentaerythritol, represented by the following formula (3):

[0064] and monoesters of fatty acids and pentaerythritol, represented by the following formula (4).

[0065] In the formulas, R1- R4 each represents a hydrocarbon chain.
[0066] The fatty acids that make up the pentaerythritol esters and fatty acids (R1 COOH, R2COOH, R3COOH, and R4COOH) are not particularly restricted as long as the pentaerythritol fatty acid esters and meet the conditions for the IOB, melting point and water, solubility and, for example, saturated fatty acids, such as C2-C30, saturated fatty acids, including acetic acid (C2) (C2 representing the number of carbon atoms, which corresponds to the number of carbon atoms of each of R1C, R2C, R3C or R4C, even below), propanoic (C3), butanoic acid (C4) and their isomers, such as 2-methylpropanoic acid (C4), pentanoic (C5) and its isomers, such as, 2-methylbutanoic acid (C5), and 2, 2-dimethylpropanoic acid (C5), hexanoic acid (e) -heptanoic acid (C7), octanoic acid (C8) and its isomers, such as, acid 2-ethylhexanoic (C8), nonanoic acid (C9), decanoic acid (C10), dodecanoic acid (C12), tetradecanoic acid (C14), acid hexadecanoic acid (C16), heptadecanoic acid (C17), octadecanoic acid (C18), eicosanoic acid (C20), docosanoic acid (C22), tetracosanoic acid (C24), hexacosanoic acid (C26), octacosanoic acid (C28) and triacontano (C30), as well as isomers of the antecedent (excluding those mentioned above).
[0067] Fatty acid can also be an unsaturated fatty acid. Examples of unsaturated fatty acids include C3-C20 unsaturated fatty acids, such as monounsaturated fatty acids, including crotonic acid (C4), myristoleic acid (C14), palmitoleic acid (C16), oleic acid (C18), oleic acid elaidic (C18), vaccenic acid (C18), gadoleic acid (C20) and eicosenoic acid (C 20), di- Unsaturated fatty acids including linoleic acid (C18) and eicosadienic (C20), tri-unsaturated fatty acids , including linolenic acids, such as oc-linolenic acid (Cis) and Y-linolenic acid (Cis), pinolenic acid (Cie), eleosearic acids, such as oc-eleoesteearic acid (C18) and β- (C18), Mead acid (C20), dihomo-i-linolenic acid (C20) and eicosatrienoic acid (C20), unsaturated fatty acids, including stearidonic acid (C20), arachidonic acid (C20) and eicosatetraenoic acid (C20) unsaturated fatty acids), including bosseopentaenoic acid (Cis) and eicosapentaenoic acid (C20) and h adducts partial idrogens among themselves.
[0068] Considering the potential for degradation by oxidation and the like, the pentaerythritol ester and a fatty acid is preferably a pentaerythritol ester and a fatty acid, which is derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid.
[0069] In addition, in order to decrease IOB and result in greater hydrophobicity, the pentaerythritol ester and a fatty acid is preferably a diester, or tetraester triester, more preferably a triester or tetraester, and even more preferably one tetraester.
[0070] In a tetraester of pentaerythritol and a fatty acid, the IOB is 0.60, if the total number of fatty acid carbons in the composition of the tetraester pentaerythritol and fatty acid, that is, the total number of carbon atoms of RiC, R2C, R3 and R4C in portions of formula (i), is i5. Thus, when the total number of fatty acid carbons in the composition of the tetraester pentaerythritol and fatty acids is about 15 or greater, the IOB satisfies the condition to be within approximately 0.00 to 0.60.
[0071] Examples of tetraesters of fatty acids and pentaerythritol include tetraesters of pentaerythritol with hexanoic acid. (C6), - heptanoic (C7), octanoic acid (C8), such as, 2-ethylhexanoic acid (C8), nonanoic acid (C9), decanoic acid (C10) and / or dodecanoic acid (C12).
[0072] In a pentaerythritol triester and a fatty acid, the IOB is 0.58, if the total number of fatty acid carbons composing the pentaerythritol and fatty acid triester, that is, the total number of carbon atoms in the F1C, R2C and R3 portions of C in formula (2), is 19. Thus, when the total number of fatty acid carbons composing the pentaerythritol and fatty acid triester is about 19 or higher, the IOB satisfies the condition of be within about 0.00 to 0.60.
[0073] In a pentaerythritol diester and a fatty acid, the IOB is 0.59, if the total number of fatty acid carbons that make up the pentaerythritol and fatty acid diester, that is, the total number of carbons of R1C or R2C portion of formula (3), is 22. Thus, when the total number of fatty acid carbons making up the fatty acid pentaerythritol diester is about 22 or greater, the IOB satisfies the condition of being within approximately from 0.00 to 0.60.
[0074] In a pentaerythritol monoester and a fatty acid, the IOB is 0.60, if the number of fatty acid carbons composing the pentaerythritol and fatty acid monoester, that is, the number of carbon atoms in the portion of formula (4), is 25. Thus, when the number of fatty acid carbon atoms in the composition of the monoester pentaerythritol and fatty acids is approximately 25 or greater, the IOB satisfies the condition of being within approximately 0, 00 to 0.60.
[0075] The effects of double bonds, triple bonds, iso-branches and tri-branches are not considered in this calculation.
[0076] Commercial products that are esters of fatty acids and pentaerythritol include UniStar H-408BRS and H-2408BRS-22 (mixed product) (both products from NOF Corp.). [(a2) ester of a chain hydrocarbon triol and at least one fatty acid]
[0077] Examples of esters of a chain hydrocarbon triol and at least one fatty acid include glycerin and fatty acid triesters, those represented by the general formula (5):

[0078] diesters of glycerin and fatty acids, represented by the following formula (6):

[0079] and monoesters of glycerin and fatty acids,
[0080] represented by the following formula (7):

[0081] where R5-R7 each represents a chain hydrocarbon.
[0082] The fatty acid composition of the glycerin ester and a fatty acid (R5 COOH, R6COOH and R7COOH) is not particularly restricted, as long as the glycerin ester and a fatty acid satisfy the conditions for. the IOB, melting point and solubility in water and, for example, the fatty acids mentioned for the "(a1) of a tetraol chain hydrocarbon ester and at least one fatty acid", that is, saturated fatty acids, can be mentioned and unsaturated fatty acids, and taking into account the potential for degradation by oxidation and the like, the ester is preferably a glycerin and fatty acid ester, which is derived from a saturated fatty acid, that is, a glycerin ester and a saturated fatty acid.
[0083] In addition, in order to decrease IOB and result in greater hydrophobicity, the glycerin ester and a fatty acid is preferably a diester or triester, and more preferably a triester.
[0084] A glycerin triester and a fatty acid is also known as a triglyceride, and examples include triester esters of glycerin and octanoic acid (C8), triester esters of glycerin and decanoic acid (C10), triester esters of glycerin and dodecanoic acid (C12) , glycerin triesters and two or more different fatty acids, and mixtures of the above.
[0085] Examples of glycerin triesters and two or more fatty acids include glycerin triesters with octanoic acid (C8) and decanoic acid (C10), glycerin triesters with octanoic acid (C8), decanoic acid (C10) and dodecanoic acid ( C12) and glycerin triesters with octane (C8), decanoic acid (C10), dodecanoic acid (C12), tetradecanoic acid (C14), hexadecanoic acid (C16) and octadecanoic acid (C18).
[0086] In order to obtain a melting point of no more than about 45 ° C, preferred triesters of glycerin and fatty acids are those that have no more than about 40, such as the total number of fatty acid carbons of the triester composition of glycerin and fatty acid, that is, the total number of carbon atoms of R5C, R6C, and R7C sections in formula (5).
[0087] In a triester of glycerin and a fatty acid, the IOB value is 0.60, when the total number of fatty acid carbons composing the triester of glycerin and fatty acid, that is, the total number of atoms carbon of R5C, R6C, and R7C in portions of formula (5), is 12. Thus, when the total number of fatty acid carbons in the glycerin and fatty acid triester composition is
[0088] about 12 or greater, the IOB satisfies the condition to be within approximately 0.00 to 0.60.
[0089] Glycerin and fatty acid triesters, being
[0090] aliphatic constituent components and therefore the potential of the human body are preferred from the point of view of safety.
[0091] Commercial products of glycerin and fatty acid triesters include coconut fatty acid tri-glycerides, NA36, PANACET 800, 800B and PANACET PANACET 81OS and tri-C2L fatty acid oil and glycerol tri-CL fatty acid glycerides (all NOF Corp. products).
[0092] A glycerin diester and a fatty acid is also known as a diglyceride, and examples include diesters of glycerin and decanoic acid (C10), diesters of glycerin and dodecanoic acid (C12), glycerin diesters and hexadecanoic acid (C16) , glycerin diesters and two or more different fatty acids, and mixtures of the above.
[0093] In a glycerin diester and a fatty acid, the IOB is 0.58, if the total number of fatty acid carbons that make up the glycerin and fatty acid diester, that is, the total number of R5C carbons and R6C portions of formula (6), is 16. Thus, when the total number of fatty acid carbons composing the glycerin and fatty acid diester is about 16 or higher, the IOB satisfies the condition of being about 0, 00 and 0.60.
[0094] Glycerin monoesters and fatty acids are also known as monoglycerides, and examples include glycerin and octadecanoic acid (C18) monoester, and glycerin and docosanoic acid (C22) monoester.
[0095] In a glycerin monoester and a fatty acid, the IOB is 0.59, if the number of fatty acid carbons that make up the glycerin monoester and fatty acids, that is, the number of R5C carbon atoms portion in formula (7), is 19. Thus, when the number of fatty acid carbon atoms in the glycerin and fatty acid monoester composition is about 19 or higher, the IOB satisfies the condition of being about 0.00 to 0.60.
[0096] [(a3) ester of a diol chain hydrocarbon and at least one fatty acid]
[0097] Examples of an ester of a diol chain hydrocarbon and at least one fatty acid include the monoesters and diesters of fatty acids with C 2 -C2-C6 chain hydrocarbon diols, such as, C2-C6 -glycols , including ethylene glycol, propylene glycol, butylene glycol, pentylene glycol and hexylene glycol.
[0098] Specifically, examples of an ester of a diol chain hydrocarbon and at least one fatty acid include diesters of C2-C6-glycols and fatty acids, represented by the following formula (8): R8COOCkH2kOCOR9 (8)
[0099] where the symbol k represents an integer of 2-6, and R8 and R9, each represents a chain hydrocarbon, and monoesters of C2 glycols-C6 and fatty acids, represented by the following formula (9): R8COOCkH2kOH (9)
[0100] where the symbol k represents an integer from 2-6, and R8 represents a chain hydrocarbon.
[0101] The fatty acid to be esterified in an ester of a C2-C6 -glycol and a fatty acid (which corresponds to R8COOH and R9COOH in formula (8) and formula (9)) is not particularly restricted, as long as the ester of C2-C6 glycol and fatty acids meets the conditions for IOB, melting point and water solubility and, for example, the fatty acids cited for the "ester (a1) of a tetraol chain hydrocarbon and at least one fatty acid ", that is, saturated fatty acids and unsaturated fatty acids, and taking into account the potential for degradation by oxidation and the like, it is preferably a saturated fatty acid.
[0102] In a butylene glycol diester (k = 4) and a fatty acid represented by the general formula (8), IOB, is 0.60, when the total number of carbon atoms in the R8C and R9C portions is 6.
[0103] Thus, when the total number of carbon atoms in a butylene glycol diester (k = 4) and a fatty acid represented by formula (8) is about 6 or greater, the IOB satisfies the condition of being about 0 , 00-0.60. In an ethylene glycol monoester (k = 2) and a fatty acid represented by the formula (9), IOB is 0.57 when the number of carbon atoms from 1 to 8, part R8C is 12. Thus, when the number total carbon atoms in the composition of an ethylene glycol monoester fatty acid (k = 2) and a fatty acid represented by the formula (9) is about 12 or greater, the IOB satisfies the condition of being about 00-0, 60.
[0104] Given the potential for degradation by oxidation and the like, the C2-C6-glycol ester and fatty acid is preferably a C2-C6-glycol and fatty acid ester, which is derived from a saturated fatty acid, 1. e., An ester of a C2-C6 glycol and a saturated fatty acid.
[0105] In addition, in order to lower IOB and result in greater hydrophobicity, the C2-C6-glycol ester and fatty acid is preferably an ester of glycol fatty acid and a glycol derivative with a greater number of carbon atoms, such as an ester of a glycol and a fatty acid derived from butylene glycol, 'pentylene glycol or hexylene glycol.
[0106] In addition, in order to lower IOB and obtain greater hydrophobicity, the ester of a C2-C6-glycol and fatty acid is preferably a diester.
[0107] Examples of commercial products of C2-C6-glycols esters and fatty acids include Compol BL and Compol BS (both products from NOF Corp.)
[0108] [(B) Ether of (BI), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (B2), a compound having a chain hydrocarbon radical and a hydroxyl group replacing a hydrogen atom in the chain hydrocarbon radical].
[0109] The (B) ether of (B1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (B2), a compound having a chain hydrocarbon radical and a hydroxyl group replacing a hydrogen atom of the hydrocarbon portion chain (hereinafter also referred to as "compound (B)") it is not necessary that all hydroxyl groups to be esterified while the IOB, melting point and water solubility are in. above mentioned intervals.
[0110] Examples of (B1), a compound having a hydrocarbon group chain and 2-4 hydroxyl groups replace hydrogens in the hydrocarbon chain radical (hereinafter also referred to as "compound (B1)") include those mentioned for "compound ( A) "that compound (A1), such as, pentaerythritol, glycerin and glycol.
[0111] Examples of (B2), a compound having a chain
[0112] hydrocarbon group and a hydroxyl group replacing a hydrogen atom in the chain hydrocarbon radical (hereinafter also referred to as "compound (B2)") include compounds in which a hydrogen in the hydrocarbon is replaced with a hydroxyl group (-OH) , such as, aliphatic, saturated aliphatic monoalcohols, including monohydric alcohols and unsaturated aliphatic monofunctional alcohols.
[0113] Examples of saturated aliphatic monohydric alcohols include C1-C20 saturated aliphatic monoalcohols, such as methyl alcohol (C1) (C1 represents the number of carbon atoms, even below), ethyl alcohol (C2), propyl alcohol (C3) and its isomers, including isopropyl alcohol (C3), butyl alcohol (C4), and its isomers, including sec-butyl alcohol (C4), and tert-butyl alcohol (C4), pentyl alcohol (C5), hexyl alcohol (C6), heptyl alcohol (C7), octyl alcohol (C8) and its isomers, including 2-ethylhexyl alcohol (C8), nonyl alcohol (C9), decyl alcohol (C10), dodecyl alcohol (C12), tetradecyl alcohol (C14), hexadecyl alcohol (C16), heptadecyl alcohol (C17), octadecyl alcohol (C18) and eicosyl alcohol '(C20), as well as their isomers other than those mentioned.
[0114] Aliphatic mono-unsaturated alcohols include those in which a single 1 CC bond of a saturated aliphatic monohydric alcohol mentioned above is replaced with a double C = C bond, such as oleyl alcohol, and, for example, these are commercially available through Novo Japan Chemical Co., Ltd., such as the RIKACOL Series and U JECOL Series.
[0115] Examples for compound (B) include (B1) an ether of a tetraol chain hydrocarbon and at least one aliphatic mono-alcohols, such as monoethers, diethers, tetraether ethers and, preferably, tetraether ethers and, more preferably tetraethers and even more preferably tetraethers, (b2) an ether of a chain hydrocarbon triol and at least one aliphatic monofunctional alcohol, such as, monoethers and diethers, preferably triethers, ethers and triethers and most preferably triethers , and (b3) an ether of a diol chain hydrocarbon and at least one aliphatic monohydric alcohol, such as, monoethers and diethers, and preferably diethers.
[0116] Examples of an ether of a tetraol chain hydrocarbon and at least one monohydric aliphatic alcohol include tetraethers, triethers, monoethers and diethers of pentaerythritol and aliphatic monohydric alcohols, represented by the following formulas (10) - (13):

[0117] where R10-R13 each represents a chain hydrocarbon.
[0118] Examples of a chain hydrocarbon triol ether and at least one monohydric aliphatic alcohol include glycerine triethers, monoethers and diethers and monohydric aliphatic alcohols represented by the following formulas (14) - (16):

[0119] wherein R14, R16 each represent a chain hydrocarbon.
[0120] Examples of an ether of a diol chain hydrocarbon and at least one aliphatic mono-alcohol include C2-C6 glycols and aliphatic, monohydric alcohols represented by the following formula (17): R17OC n H2n OU18 (17)
[0121] where n is an integer from 2-6, and R17 and R18, each, a chain hydrocarbon, and monoethers of C2-C6 glycols and aliphatic, monohydric alcohols represented by the following formula (18): R17OCnH2nOH ( 18)
[0122] where n is an integer from 2-6, and R17 is a chain hydrocarbon.
[0123] In the pentaerythritol tetraether and in an aliphatic monohydric alcohol, the IOB is 0.44, when the total number of carbon atoms in the aliphatic monohydric alcohol composing the pentaerythritol tetraether and the aliphatic monohydric alcohol, that is, the number total carbon atoms of R10, R11, R12 and R13 portions in formula (10), is 4. Thus, when the total number of carbon atoms of aliphatic monohydric alcohol composing a pentaerythritol tetraether and an aliphatic monohydric alcohol is approximately 4 or higher, the IOB value satisfies the condition to be within about 0.00 to 0.60.
[0124] In the pentaerythritol triether and in an aliphatic monohydric alcohol, the IOB is 0.57 when the total number of carbon atoms in the aliphatic monohydric alcohol that make up the pentaerythritol triether and the aliphatic monohydric alcohol, that is, the number total carbon atoms of R10, R11 and R12 portions in formula (11), is 9. Thus, when the total number of carbon atoms of aliphatic monohydric alcohol composing a pentaerythritol triether and an aliphatic monohydric alcohol of about 9 or higher, the IOB value satisfies the condition to be within about 0.00 to 0.60.
[0125] In pentaerythritol diester and in an aliphatic monohydric alcohol, the IOB is 0.60, when the total number of carbon atoms in the aliphatic monohydric alcohol that make up the pentaerythritol diester and the aliphatic monohydric alcohol, that is, the total number of carbon atoms of R10 and R11 in portions of formula (12), is 15. Thus, when the total number of carbon atoms of aliphatic monohydric alcohol composing a pentaerythritol ether and an aliphatic monohydric alcohol of about 15 or higher, the IOB value satisfies the condition to be within about 0.00 to 0.60.
[0126] In the pentaerythritol monoether and in an aliphatic monohydric alcohol, the IOB is 0.59 when the number of carbon atoms in the aliphatic monohydric alcohol composing the pentaerythritol monoether and the aliphatic monohydric alcohol, that is, the number of atoms carbon content of R10 portion in formula (13), is 22.
[0127] Thus, when the number of carbon atoms of the aliphatic type monohydric alcohol composes a pentaerythritol monoether and an aliphatic monohydric alcohol is about 22 or higher, the IOB value satisfies the condition of being within about 0.00 to 0.60.
[0128] In the glycerin triether and in a monohydric alcohol aliphatic portion, the IOB is 0.50, when the total number of carbon atoms in the aliphatic monohydric alcohol that make up the glycerin triester and aliphatic monohydric alcohol, that is, the total number of carbon atoms of R14, R15 and R16 in formula portions (14), is 3.
[0129] Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol composing a glycerin triether and an aliphatic monohydric alcohol is about 3 or more, the IOB value satisfies the condition of being within approximately 0.00 to 0.60.
[0130] In glycerin diets and a monohydric alcohol aliphatic portion, the IOB is 0.58, when the total number of carbon atoms in the aliphatic monohydric alcohol composing the glycerin ether and aliphatic monohydric alcohol, that is, the total number of carbon atoms of R14 and R15 in portions of formula (15), is 9. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol composing a glycerin diether and an aliphatic monohydric alcohol is approximately 9 or higher, the IOB value satisfies the condition to be within approximately 0.00 to 0.60.
[0131] In glycerin monoether and in an aliphatic monohydric alcohol, the IOB is 0.58 when the number of carbon atoms in the aliphatic monohydric alcohol composing the glycerin monoether and aliphatic monohydric alcohol, that is, the number of atoms carbon of R14 in the formula portion (16), is 16.
[0132] Thus, when the number of carbon atoms in the aliphatic monohydric alcohol comprising a glycerin monoether and an aliphatic mono-alcohol is approximately 16 or higher, the IOB value satisfies the condition of being within approximately 0.00 to 0.60.
[0133] In a butylene glycol diester (n = 4) and aliphatic monohydric alcohol represented by the general formula (17), the IOB is 0.33 when the total number of carbon atoms in R17 and R18 portions is 2. Thus , when the number of carbon atoms of the aliphatic monohydric alcohol composing a butylene glycol diether (n = 4) and an aliphatic monohydric alcohol represented by the formula (17) is approximately 2 or higher, the IOB values satisfy the condition of being within about 0.00 to 0.60. In addition, in an ethylene glycol monoether (n = 2) and aliphatic monohydric alcohol represented by the general formula (18), the IOB, is 0.60, when the number of carbon atoms in R17, part is 8.
[0134] Thus, when the number of carbon atoms of the aliphatic monofunctional alcohol in an ethylene glycol monoether (n = 2) and an aliphatic monohydric alcohol represented by the formula (18) is about 8 or greater, the IOB value satisfies the condition to be within approximately 0.00 to 0.60.
[0135] Compound (B) can be produced by dehydrating condensation of the compound (B1) and the compound (B2), in the presence of an acid catalyst.
[0136] [(C) (C1) ester of a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a chain hydrocarbon radical and 2-4 carboxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (C2) , a compound having a chain hydrocarbon radical and a hydroxyl group replacing a hydrogen atom in the chain hydrocarbon radical].
[0137] The "(C) ester of (C1) of a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a radical hydrocarbon chain and 2-4 carboxyl groups, substituting hydrogen atoms in the hydrocarbon radical e ( C2), a compound having a chain hydrocarbon radical and a hydroxyl group, replacing a hydrogen atom in the chain hydrocarbon radical (hereinafter also referred to as "compound (C)") it is not necessary that all the sterile carboxyl groups lifted to be as long as the IOB, melting point and water solubility are within the ranges mentioned above.
[0138] Examples of (C1) of a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a chain hydrocarbon radical and 2-4 carboxyl groups replacing hydrogen atoms in the chain hydrocarbon radical (hereinafter referred to as "compound ( C1) ") include hydrocarbon chain carboxylic acids with 2-4 carboxyl groups, such as the chain of dicarboxylic acids, including alkanedicarboxylic acid hydrocarbons such as ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, hexanedioic acid heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acids, including alkanetricarboxylic acids, such as propanethroic acid, butanethroic acid, pentanethroic acid, hexanethroic acid, heptanethroic acid, and octetraetric acid tetracarboxylic acids chain hydrocarbons, including acids alkanetetracarboxylic acid such as, butanetetraicoic, hexanetetraicoic acid, hexanetetraóico acid, heptanetetraóico acid, octanetetraóico acid, nonanetetraóico acid and decanetetraóico acid.
[0139] The compound (C1) of the hydroxy acid chain includes hydrocarbons with 2-4 carboxyl groups, such as malic acid, tartaric acid, citric acid and isocitric acid, alkoxy chain hydrocarbon acids with 2-4 carboxyl groups, as for example, O-acetylcitric acid, and oxoacids chain hydrocarbons with 2-4 carboxyl groups.
[0140] (C2) The compound having a chain hydrocarbon radical and a hydroxyl group, replacing a hydrogen atom in the chain hydrocarbon radical include those mentioned for "compound (B)", such as, "aliphatic monovalent alcohols.
[0141] Compound (C) can be (c1) an ester, for example, a tetraester monoester, diester or triester, preferably a diester, triester and tetraester, more preferably a triester and tetraester or even more preferably a tetraester , of a hydrocarbon chain, tetracarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with 4 carboxyl groups, and at least one monohydric aliphatic alcohol, (c2), an ester, for example, a monoester, diester or triester, preferably a diester or triester and more preferably a triester, of a hydrocarbon chain, tricarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with 3 carboxyl groups, and at least one aliphatic monohydric alcohol or (c3), an ester, for example, a mono -ester or diester, and preferably a diester, of a hydrocarbon chain dicarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with two carboxyl groups, and at least one monohydric aliphatic alcohol.
[0142] Examples for compound (C) include dioctyl adipate and tributyl-S acetyl citrate, of which there are commercially available products.
[0143] [(D) The compound having a chain hydrocarbon radical and a bond selected from the group consisting of an ether bond (-0-), the carbonyl bond (-CO-), ester bond (-COO-) and bonding carbonate (-OCOO-) inserted between a single CC bonding of the chain hydrocarbon unit].
[0144] The compound (D) with a chain hydrocarbon unit and a bond selected from the group consisting of an ether bond (-0-), carbonyl bond (-CO-), ester bond (-COO) and carbonate of bond (-OCOO-) inserted between a single CC bond of the chain hydrocarbon radical (hereinafter also referred to as "compound (D)") can be (d1) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d2 ) a dialkyl ketone, (d3) an ester of a fatty acid and an aliphatic monohydric alcohol. or (d4) a dialkyl carbonate.
[0145] [(d1) -ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]
[0146] The ethers of monoaliphatic and monoalcoholic alcohols include compounds with the following formula (19): R19OU R20 (19)
[0147] where R19 and R20 each represent a chain
[0148] hydrocarbon.
[0149] The aliphatic monohydric alcohol composing the EO (corresponding to R19ROH and R20OH in the formula (19)), is not particularly restricted, as long as the ether satisfies the conditions for the IOB, melting point and water solubility and therefore For example, it may be one of the monofunctional aliphatic alcohols mentioned for "compound (B)."
[0150] In an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the IOB, is 0.50, when the total number of carbon atoms of the aliphatic monofunctional alcohols that make up the ether, that is, the total number of carbon atoms of R19 and R20 in formula (19) portions, is 2, and therefore, when the total number of carbon atoms in the monofunctional aliphatic alcohols that make up the ether is about 2 or higher, this condition is the IOB satisfied. However, when the total number of carbon atoms in the monofunctional aliphatic alcohols that make up the ether is about 6, the solubility in water is as high as about 2 g, which is problematic from the point of view of vapor pressure. also. In order to satisfy the solubility condition of about 0.00-0.05 g of water, the total number of carbon atoms of the monofunctional aliphatic alcohols that make up the ether is preferably about 8 or more.
[0151] [(d2) dialkyl ketone]
[0152] The dialkyl ketone can be a compound with the following formula (20): R21COR22 (20)
[0153] where R21 and R22 are each an alkyl group.
[0154] In a dialkyl ketone, the IOB is 0.54, when the total number of carbon atoms of R21 and R22 is 5, and therefore this condition for the IOB is satisfied if the total number of atoms carbon is about 5 or higher. However, when the total number of dialkyl ketone carbons is about 5, the solubility in water is as high as about 2 grams. Therefore, in order to satisfy the condition of a solubility of about 0.00-0.05 g of water, the total number of dialkyl ketone carbons is preferably about 8 or higher. In consideration of the vapor pressure, the number of dialkyl ketone carbon atoms is preferably about 10 or more, and more preferably about 12 or greater.
[0155] If the total number of dialkyl ketone carbon atoms is about 8, such as 5-nonanone, for example, the melting point is approximately -50 ° C and the vapor pressure is about 230 Pa at 20 ° C.
[0156] The dialkyl ketone can be a commercially available product, or it can be obtained by a known method, such as by oxidizing a secondary alcohol with chromic acid or the like.
[0157] [(d3) fatty acid ester and aliphatic monohydric alcohol]
[0158] Examples of esters of fatty acids and mono-functional aliphatic alcohols include compounds that have the following formula (21): R23COOR24 (21)
[0159] where R23 and R24 each represent a hydrocarbon chain.
[0160] Examples of fatty acids that make up these esters (Corresponding to R23COOH in formula (21)) include the fatty acids cited for "(a1) an ester of a tetraol chain hydrocarbon and at least one of fatty acids" and, specifically, these include saturated fatty acids and unsaturated fatty acids, with saturated fatty acids, the potential for degradation by oxidation and the like being preferred. The aliphatic monohydric alcohol composing the ester (corresponding to R24OH in formula (21)) may be one of the monofunctional aliphatic alcohols mentioned for "compound (B)."
[0161] In an ester of such a fatty acid and aliphatic monohydric alcohol, the IOB is 0.60, when the total number of carbon atoms of the fatty acid and aliphatic monohydric alcohol, that is., The total number of atoms carbon of R23C and R24 in the portion of formula (21), is 5, and therefore this condition for the IOB is satisfied when the total number of carbon atoms of R23C and R24 in the portion is about 5 or higher.
[0162] However, with butyl ethyl in which the total number of carbon atoms is 6, the vapor pressure is raised to 2000 greater than Pa. Considering the vapor pressure, therefore, the total number of carbon atoms carbon is preferably about 12 or higher. If the total number of carbon atoms is about 11 or greater, it will be possible to satisfy the solubility condition of about 0.00-0.05 g of water.
[0163] Examples of esters of fatty acids and monohydric alcohols such aliphatics include esters of dodecanoic acid (C12) and dodecyl alcohol (C12) and esters of tetradecanoic acid (C14) and dodecyl alcohol (C12), and examples of commercial products from esters of fatty acids and monohydric alcohols such aliphatics include ELECTOL E20 and ELECTOL WE40 (products of both NOF Corp.)
[0164] [(d4) dialkyl carbonate]
[0165] The dialkyl carbonate can be a compound of the following formula (22): R25OC (= 0) or 26 (22)
[0166] where R25 and R26 are each an alkyl group.
[0167] In a dialkyl carbonate, the IOB is 0.57, when the total number of carbon atoms of R25 and R26 is 6, and therefore this condition for the IOB is satisfied if the total number of carbon atoms of R25 and R26 is about 6 or greater.
[0168] In consideration of water solubility, the total number of carbon atoms of R25 and R26 is preferably about 7 or more and more preferably about 9 or more.
[0169] Dialkyl carbonate can be a commercially available product, or it can be synthesized by reaction between phosgene and an alcohol, the reaction between formic chloride and an alcohol or an alcoholate, or the reaction between silver carbonate and an iodide alkyl.
[0170] [(E) C3-C6 alkylene glycol polyoxy, or alkyl or alkyl ether ester] A (E) C3-C6 alkylene glycol, or alkyl ester or its alkyl ether (hereinafter also referred to as "compound (E)") can be (EI), a polyoxy-C3-C6 alkylene glycol, (e2) an ester of a polyoxy-C3-C6 alkylene glycol and at least one fatty acid, or (e3 ) a C3-C6-glycol polyoxy ether and at least one monofunctional aliphatic alcohol.
[0171] These will now be explained.
[0172] [(e1) C3-C6 alkylene glycol polyoxy]
[0173] C3-C polyoxy 6 alkylene glycols refer to i) one or more homopolymers having a unit selected from the group consisting of oxy C3 _6 alkylene units, such as oxypropylene unit, oxybutylene unit, oxypentylene unit and unit oxyhexylene and having hydroxyl groups at both ends, ii) one or more block copolymers with 2 or more units selected from oxy C3 - 6 alkylene units, such as the oxypropylene unit, oxybutylene unit, oxypentylene unit and oxyhexylene unit and having hydroxyl groups at both ends, or iii) random copolymers having 2 or more oxy units selected from C3 -6 alkylene units, such as oxypropylene unit, oxybutylene unit, oxypentylene unit and unit oxyhexylene and having hydroxyl groups at both ends.
[0174] Polyoxy-C3-C 6 alkylene glycol is represented by the following formula (23): HO- (CmH2mO) n-H (23)
[0175] where m is an integer of 3-6.
[0176] In polyethylene glycol (corresponding to
[0177] homopolymer of formula (23) where m = 2), when n> 45, the IOB condition of about 0.00-0.60 is satisfied, but when n> 45, the average molecular weight by weight 'exceeds about 2,000.
[0178] In addition, confirmation by the present inventors revealed that for polypropylene glycol (corresponding to the homopolymer of formula (23) where m = 3), an IOB of about 0.00-0.60, from a not exceeding about 45 ° C and a melting solubility of about 0.00-0.05 g in 100 g of water at 25 ° C, the water is satisfied only when the average molecular weight in weight is about 1,000 or greater.
[0179] Thus, a polypropylene glycol resin does not fall within the range of the aforementioned blood modifying agent.
[0180] Therefore, propylene glycol should be included in the (EI) C3-C6 alkylene glycol only as a random polymer or copolymer with another glycol.
[0181] The value of n in formula (23) is such that the C3-C6 alkylene glycol polyoxy has an IOB of about 0.00-0.60, a point of no more than about 45 ° C and a water solubility of about 0.00-0.05 g in 100 g of water at 25 ° C. Fusion
[0182] For example, when formula (23) is polybutylene glycol (homopolymer, m = 4), the IOB is 0.57 when the symbol n = 7. Thus, when formula (23) is polybutylene glycol (Homopolymer , m = 4), with the condition for the IOB is satisfied when the symbol n is equal to or greater than about 7.
[0183] Examples of commercial C3-C6 alkylene glycol polyoxy products include UNIOL ™ PB-500 and SP-700 (both products from NOF Corp.) [(e2) ester of a polyoxy C3-C6 alkylene glycol and at less a fatty acid]
[0184] Examples of an ester of a C3-C6 polyoxy, alkylene glycol and at least one fatty acid include the C3-C6 alkylene glycols mentioned for "(e1) C3-C6 alkylene glycol", wherein one or both OH ends were esterified with fatty acids, that is, monoesters and diesters.
[0185] Examples of fatty acids to esterify in the polyoxy-C3-C6 ester mentioned for "(a1)
[0186] Ester of a tetraol chain hydrocarbon and at least one fatty acid ", and specifically these include saturated fatty acids and unsaturated fatty acids, saturated fatty acids, with the potential for oxidative degradation and the like being preferable.
[0187] [(e3) C3-C6-glycol polyoxyether and at least one monohydric aliphatic alcohol]
[0188] Examples of a C3-C6-glycol polyoxy ether and at least one monofunctional aliphatic alcohol include the C3-C6 to C3-C6 glycols mentioned for "(e1) C3-C6-glycol polyoxy", wherein one or both OH ends have been etherified by an aliphatic monohydric alcohol, that is, monoethers and diethers.
[0189] In a C3-C6-glycol polyoxy ether and at least one monohydric aliphatic alcohol, the aliphatic monohydric alcohol being etherified may be an aliphatic monohydric alcohol among those mentioned for "compound (B)."
[0190] [(F) chain hydrocarbons]
[0191] The chain hydrocarbon has a value of 0 and inorganic thus an IOB of 0.00, whereas the solubility in water is also about 0 g, and therefore, if the melting point is not more than about 45 ° C, can be included among the aforementioned blood modifying agents.
[0192] Examples of these include chain hydrocarbons (f1) of the alkane chain, for example, linear and branched alkanes, linear alkanes and alkanes generally include those that have no more than 22 carbon atoms, taking into account the melting point not more than about 45 ° C.
[0193] In consideration of vapor pressure, they generally include those with 13 or more carbon atoms. Branched alkanes generally include those with 22 or more carbon atoms, since their melting points are often lower than linear alkanes, given the same number of carbon atoms.
[0194] Examples of commercially available products include PARLEAM 6 hydrocarbons (NOF Corp.)
[0195] The blood modifying agent has been found to have at least the function of decreasing blood viscosity and surface tension, which will be considered in detail in the examples. Menstrual blood to be absorbed by the absorbent article contains proteins from the endometrial wall, for example, unlike ordinary blood, which act together to bind blood cells, in such a way that the blood cells constitute a Rouleau state. Therefore, menstrual blood to be absorbed by the absorbent article tends to have high viscosity, and, if the top sheet is a non-woven or woven fabric, menstrual blood becomes trapped between the fibers, creating a sticky sensation. residual to the wearer, while menstrual blood also diffuses over the surface of the topsheet and tends to escape.
[0196] In the absorbent article of the present description, the top sheet comprises a blood modifying agent that has been found to have at least the function of decreasing blood viscosity and surface tension and therefore if the top sheet is a non-woven fabric or tissue, the clogging of menstrual blood between the top sheet fibers is reduced and menstrual blood can quickly migrate from the upper sheet to the absorbent body.
[0197] Furthermore, in the absorbent article of the present description, the blood modifying agent has a melting point of no more than about 45 ° C, and therefore either liquid or solid at normal temperature (25 ° C), when it contacts the body fluid at about 30-40 ° C, it liquefies (or is a liquid) and readily dissolves in the body fluid.
[0198] In addition, the blood modifying agent, which has an IOB of about 0.00 to 0.60 and has a high organism readily infiltrates between the blood cells, and is therefore stabilizing the blood cells. blood and can prevent the formation of a Rouleau structure by blood cells.
[0199] Since the blood modifying agent stabilizes blood cells and helps prevent the formation of a Rouleau structure of the blood cells, which facilitates the absorption of menstrual blood by the absorbent body. For example, with an absorbent article comprising a superabsorbent acrylic polymer, or SAP, the absorption of menstrual blood is known to lead to coverage of the surface of SAP by Rouleau-formed and blood-inhibiting globules.
[0200] SAP absorption performance, but presumably blood cell stabilization allows SAP absorption performance to be exposed more easily. In addition, the blood-modifying agent that has a high affinity for erythrocytes protects erythrocyte membranes, and therefore can minimize erythrocyte destruction.
[0201] Any liquid-permeable top sheet, which is normally used in the art, can be used without any special restrictions, and for example, it can be a sheet-like material that has a structure that allows water to permeate, such as , a porous film, fabric, non-woven fabric or the like. The fibers that make up that of a fabric or non-woven fabric can be natural fibers or chemical fibers, with examples of natural fibers including cellulose, such as, cellulose earth and cotton, and examples of chemical fibers, including regenerated cellulose, such as rayon, rayon and cellulose fibrils, semi-synthetic, such as acetate and triacetate, hydrophobic thermoplastic chemical fibers, and hydrophilicized hydrophobic synthetic thermoplastic fibers.
[0202] Examples of chemical thermoplastic hydrophobic fibers include polyethylene (PE), polypropylene (PP) and polyethylene terephthalate (PET) monofilaments, and fibers including PE and PP graft polymers.
[0203] Examples of non-woven fabrics include air through non-woven fabrics, spunbond non-woven fabrics, attachment point, non-woven fabrics, non-woven fabrics, needle spun cord fabrics perforate non-woven fabrics and non-woven fabrics obtained by extrusion , as well as combinations thereof (such as SMS and the like).
[0204] Liquid-impermeable back sheets include films comprising PE and PP, air-permeable films, air-permeable resin resin films bonded to interlaced or non-woven fabric, spun cord fabrics and non-woven layers fabrics multiple, such as SMS. In view of the flexibility of the absorbent article, a low density polyethylene (LDPE) film with a base weight of about 15-30 g / m2, for example, is preferred.
[0205] An embodiment of the absorbent article according to the disclosure may comprise a second sheet between the liquid-permeable top sheet and the absorbent body. The second sheet can be any of the same examples as for the liquid permeable top sheet.
[0206] The first example of the body is an absorbent that has an absorbent core covered with a core shell.
[0207] Examples of components for the absorbent core include hydrophilic fibers, including cellulose, such as ground pulp or cotton, of regenerated cellulose, such as rayon, or rayon fibrils, semi-synthetic cellulose, such as acetate or triacetate, particle polymers, filaments, thermoplastic hydrophobic polymer fibers, chemical and • hydrophilicized thermoplastic chemical hydrophobic fibers, as well as, combinations of the above.
[0208] The absorbent core component can also be a superabsorbent polymer, for example, granules of a sodium acrylate copolymer or the like.
[0209] The core wrap is not particularly restricted, as long as it is a substance that is permeable to liquids and with a barrier property that does not allow permeation. of the absorbent polymer, and can be a fabric or non-woven fabric, for example. The fabric or a non-woven fabric can be made of a natural fiber, chemical fiber, fabric, or the like.
[0210] A second example of an absorbent body is formed from an absorbent sheet or a polymer sheet, with a thickness preferably about 0.3-5.0 mm. The absorbent polymer sheet or sheet can generally be used without any particular restrictions, as long as it is one that can be used on an absorbent article such as a sanitary napkin.
[0211] The modifying agent can be present in the blood anywhere in the planar direction of the top sheet, such as, through the entire top sheet> or the center region, close to the vaginal orifice.
[0212] When the liquid-permeable top sheet is formed from a nonwoven or woven fabric, the blood modifying agent preferably does not fill the voids between the fibers of the nonwoven or woven fabric, and , for example, the blood modifying agent can be attached as droplets or particles on the fiber surface of the nonwoven fabric, or which cover the fiber surfaces. On the other hand, when the liquid-permeable top sheet is formed of a porous film, the blood modifying agent preferably does not fill the holes in the porous film, and, for example, the modifying agent can be blood attached as droplets or particles on the surface of the porous film. This is because, if the blood modifying agent fills the voids between the fibers of the nonwoven or tissue, or fills the holes in the porous film, the migration of the liquid absorbed by the absorbent body can be inhibited.
[0213] The blood modifying agent preferably also has a large surface area, to allow rapid migration to the absorbed liquid, and a blood modifying agent present as droplets or particles, preferably has a small droplet / particle size.
[0214] In an embodiment where the absorbent article has a second sheet, the second sheet may comprise a blood-modifying agent. In addition, according to an embodiment of the absorbent article of the present description, the absorbent body may comprise a blood-modifying agent.
[0215] In this absorbent article, the top sheet comprises the blood modifying agent at a base weight in the range preferably 1-30 g / m2, more preferably 2-20 g / m2 and, more preferably 3-10 g / m2. If the base weight of the blood modifying agent is less than about 1 g / m2, the effect of modifying the blood tends to be insufficient and, if the base weight of the blood modifying agent is increased, the viscosity during wear will tend to be increased.
[0216] When the material to be coated with the blood modifying agent, such as the top sheet, is a non-woven fabric or porous film made of a synthetic resin, it is preferably coated with or mixed with a hydrophilic agent for hydrophilic treatment. If the parent material is hydrophilic, since it is subsequently coated with a modifying agent with a lipophilic IOB of about 0.00-0.60 and of high organicity, dispersed lipophilic regions and hydrophilic regions will not be created scarcely.
[0217] This allows the presumably consistent absorption performance to be displayed for menstrual blood, which consists of hydrophilic components (blood plasma, etc.) and lipophilic components (blood cells, etc.).
[0218] There are no particular restrictions on the method of coating the blood modifying agent, and coating can be carried out with heating as needed, using a non-contact coating, for example, a spiral coating machine, coating by curtain, spray coating or dip coating or a contact coating or the like. The non-contact coating is preferable from the point of view of uniformly dispersing the drop or particulate modifying agent at all, and from the point of view of not causing damage to the material.
[0219] The blood modifying agent can be coated directly, if it is a liquid at room temperature, or it can be heated to decrease viscosity, and when it is a solid at room temperature, it can be heated for liquefaction and coated through of a hot seam control (HMA) weapon. By increasing the air pressure of the HMA gun control seam, it is possible to coat the blood modifying agent as fine particles.
[0220] The blood of the modifying agent can be coated during the production of the topsheet material, such as non-woven fabric, or it can be coated on the manufacturing line for the production of the absorbent article.
[0221] From the point of view of minimizing investment in equipment, the modifying agent is preferably coated with blood on the manufacturing line of the absorbent article, and, in order to prevent the spilling of the blood modifying agent that may contaminate the line , the modifying agent is preferably coated with blood, during a phase, downstream of the manufacturing line, and, specifically, immediately before the encapsulation of the product in an individual package.
[0222] The blood modifying agent can also have an effect as a lubricant.
[0223] When the top sheet is a nonwoven fabric, it is possible to reduce the friction between the fibers, thus improving the flexibility of the nonwoven fabric as a whole. When the top sheet is a resin film, it is possible to reduce the friction between the top sheet and the skin.
[0224] The absorbent article is preferably an absorbent article intended for the absorption of blood, such as a sanitary napkin, the lining of underwear or the like.
[0225] With an absorbent article of the present description, there is no need for components, such as, and emollient immobilizing agents, unlike absorbent articles containing a skin care composition, lotion composition or the like. In one or more embodiments, it is sufficient to apply the top sheet of the blood modifying agent alone. EXAMPLES
[0226] Several examples will now be explained by way of examples, with the understanding that the revelation is not intended to be limited to examples. [Example 1]
[0227] [Evaluation of the rewetting rate and absorbent body Migration rate]
[0228] A commercially available sanitary napkin has been prepared.
[0229] The hygienic absorbent was formed from a top sheet, formed by a hydrophilic agent treated with air through non-woven fabric (fiber composite composed of polyester and polyethylene terephthalate, base weight: 35 g / m2) , a second sheet, formed by a non-woven air-woven apparatus (composed of polyester fiber composite and polyethylene terephthalate, base weight: 30 g / m2), an absorbent body comprising cellulose (weight of base: 150-450 g / m2, increased the central section), a super-absorbent acrylic polymer (base weight: 15 g / m2) and the fabric as a core wrap, a treated water repellent side sheet, and a backsheet made of a polyethylene film.
[0230] The blood modifying agents used for the experiment are listed below.
[0231] [(a1) of a tetraol chain hydrocarbon ester and at least one fatty acid]
[0232] ■ product H-L ISTAR 408BRS, from NOF Corp
[0233] Tetrapentaerithritol 2 ethilhexanoate, weight average molecular weight: about 640 • product U ISTAR H-2408BRS-22, from NOF Corp
[0234] Mixture of neopentyl glycol di-2-ethylhexanoate 2-ethyl-hexanoate tetrapentaerithritol (58:42, mass ratio), average molecular weight by weight: about 520
[0235] [(a2) ester of a chain hydrocarbon triol and at least one fatty acid] • Cetiol SB45DEO, Cognis Japan
[0236] Glycerin and fatty acid triester, with oleic acid or stearylic acid like fatty acid. • SOI42, product of NOF Corp
[0237] Glycerin and triester fatty acids with C14 fatty acids
[0238] acid: CI6 fatty acid: C18 fatty acids: C20 fatty acid
[0239] (Including both saturated and unsaturated fatty acids), at a mass ratio of about 0.2: 11: 88: 0.8, average molecular weight: 880 • Tri-C2L fatty acid glyceride oil, the NOF Corp product
[0240] Glycerin and fatty acid triester with C8 fatty acids: C10 fatty acids: C12 fatty acid in a mass ratio of about 37: 7: 56, the average molecular weight by weight: about 570 • Tri oil -CL glyceride fatty acids, the product of NOF Corp
[0241] Glycerin and fatty acid triester in C8 fatty
[0242] acid: C12 fatty acid in a mass ratio of about 44:56, the average molecular weight: about 570 • PANACET 810S, product of NOF Corp
[0243] Glycerin and fatty acid triester with C8 fatty acids: C10 fatty acid at a mass ratio of about 85:15, average molecular weight by weight: about 480 • PANACET 800, product of NOF Corp
[0244] Glycerin and fatty acid triester with octanoic acid (C8), like the whole fatty acid portion, the average molecular weight by weight: about 470 • PANACET 800B, product of NOF Corp
[0245] Glycerin and fatty acid triester with 2-ethylhexanoic acid (C8), like the whole fatty acid portion, the average molecular weight by weight: about 470 • NA36, product of NOF Corp
[0246] Glycerin and triester fatty acid with C16 fatty acid C18 fatty acid: C20 fatty acid (including saturated fatty acids and unsaturated fatty acids), at a mass ratio of about 5: 92: 3, the molecular weight of average weight: about 880 • Tri-coco glyceride fatty acids, the product of NOF Corp
[0247] Glycerin and fatty acid triester with C8 fatty acid: C10 fatty acid: C12 fatty acid: C14 fatty acid: C16 fatty acids (including both saturated and fatty acids)
[0248] Unsaturated fatty acids) at a mass ratio of about
[0249] 4: 8: 60: 25: 3, the average molecular weight: 670 • diglyceride caprylic acid, product of NOF Corp
[0250] Glycerin and diester of fatty acid with octanoic acid as fatty acid, molecular weight of the average weight:
[0251] approximately 340
[0252] [(a3) ester of a diol hydrocarbon and at least one fatty acid] • Compol BL, product of NOF Corp
[0253] Dodecanoic acid (C12) butylene glycol monoester, average molecular weight: about 270 • Compol BS, product of NOF Corp
[0254] Octadecanoic acid (C18) butylene glycol monoester, average molecular weight: about 350 • UniStar H-208BRS, product of NOF Corp
[0255] Neopentylglycol di-2-ethylhexanoate, molecular weight of average weight: about 360.
[0256] [(c2) Ester of a hydrocarbon chain, tricarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with 3 carboxyl groups, and at least one monohydric aliphatic alcohol] • tributyl O-acetylcitrate, product of Tokio Kasei Kogio Co., Ltd.
[0257] Average molecular weight by weight: about 400 [(c3 Ester of a hydrocarbon chain dicarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with two carboxyl groups, and at least one monohydric aliphatic alcohol] • dioctyl adipate, product of Wako Puré Chemical Industries, Ltd.
[0258] - Average molecular weight: about 380 [0131]
[0259] [(d3) fatty acid ester and aliphatic monohydric alcohol] • ELECTOL WE20, product of NOF Corp
[0260] Dodecanoic acid ester (C12) and dodecyl alcohol (C12), the average molecular weight: about 360 • ELECTOL WE40, product of NOF Corp
[0261] Ester of tetradecanoic acid (C14) and dodecyl alcohol (C12), the average molecular weight: about 390
[0262] [(e1) C3-C6 alkylene glycol polyoxy] • UNIOL PB500, product of NOF Corp
[0263] Polybutylene glycol, average molecular weight: about 500 • UNIOL PB700, product of NOF Corp
[0264] Polyoxybutyleneepolyoxypropylene glycol, average molecular weight by weight: about 700
[0265] [(f1) alcane Chain] • PARLEAM 6, product of NOF Corp
[0266] Branched hydrocarbons, produced by copolymerization of liquid isoparaffin, isobutene and n-butene, followed by the addition of hydrogen, the degree of polymerization: approximately 5-10 molecular weight, the average weight: approximately 330 [0134]
[0267] [Other components] • NA50, product of NOF Corp
[0268] Glycerin and fatty acid triester obtained
[0269] addition of hydrogen to NA36 reduced proportion of starting unsaturated fatty acid double bonds
[0270] material, weight average molecular weight: about 880 • (caprylic / capric acid) monoglyceride, product of NOF Corp
[0271] Glycerin and fatty acid monoester, with octanoic acid (C8) and decanoic acid (C10), at a mass ratio of about 85:15, average molecular weight by weight: about 220 • Monomuls 90-L2 monoglyceride of lauric acid, product of the company Cognis Japan • isopropyl citrate, the product of Tokio Kasei Kogio Co., Ltd.
[0272] Average molecular weight by weight: about 230 • Diisostearyl malate
[0273] Average weight of molecular weight: about 640 • UNIOL PB1000R, product of NOF Corp
[0274] Polybutylene glycol, average molecular weight: about 1,000 • UNIOL D-400, product of NOF Corp
[0275] Polypropylene glycol, average molecular weight by weight: about 400 • UNIOL D-1000, product of NOF Corp
[0276] Polypropylene glycol, average molecular weight by weight: about 1000 • UNIOL D-1200, product of NOF Corp
[0277] Polypropylene glycol, average molecular weight by weight: about 1160 • UNIOL D-3000, product of NOF Corp
[0278] Propylene glycol, average molecular weight: about 3,000 • UNIOL D-4000, product of NOF 'Corp.
[0279] Polypropylene glycol, average molecular weight by weight: about 4000 • PEG1500, product of NOF Corp
[0280] Polyethylene glycol, average molecular weight: about 1,500-1,600 • WILBRITE cp9, product of NOF Corp
[0281] Polybutylene compound glycol with OH groups at both ends esterified by hexadecanoic acid (C16), average molecular weight: about 1,150 • UNILUBE MS-70K, product of NOF Corp
[0282] Polypropylene glycol stearyl ether, about 15 repeat units, average weight molecular weight:
[0283] approximately 1,140 • NONION S-6, the product of NOF Corp
[0284] Polyoxyethylene monostearate, of about 7 repeated units, the average molecular weight:
[0285] approximately 880 • UNILUBE 5TP-300KB
[0286] Polyoxyethylenepolioxypropylene pentaerythritol ether, produced by adding 5 moles of ethylene oxide and 65 moles of propylene oxide to 1 mole of
[0287] pentaerythritol, average molecular weight: 4130 [0139] • WILBRITE s753, product of NOF Corp
[0288] Polyoxyethylenepolyoxypropylene glycerin polyoxybutylene, average molecular weight: approximately 960 • UNIOL TG-330, product of NOF Corp
[0289] Polypropylene glycol glycerol ether,
[0290] approximately 6 repeating units, average molecular weight: about 330
[0291] Product • UNIOL TG-1000, from NOF Corp
[0292] Polypropylene glycol glycerol ether,
[0293] about 16 repetition units, average weight
[0294] molecular weight: about 1,000
[0295] ■ product UNIOL TG-3000, by NOF Corp
[0296] Polypropylene glycol glycerol ether,
[0297] about 16 repetition units, average weight
[0298] molecular weight: about 3000 • product UNIOL TG-4000, from NOF Corp
[0299] Polypropylene glycol glycerol ether,
[0300] about 16 repetition units, average weight
[0301] molecular weight: about 4000 • UNILUBE DGP-700, product of NOF Corp
[0302] Polypropylene glycol diglyceryl ether,
[0303] approximately 9 repeating units, average molecular weight: about 700 • UNIOX HC60, product of NOF Corp
[0304] Polyoxyethylene hydrogenated castor oil, average molecular weight: about 3,570 • Vaseline, product of Cognis Japan • petroleum derived hydrocarbon, semi-solid
[0305] The IOBs, melting points, water solubility and the average molecular weights of the sample weight are shown in Table 2.
[0306] Water solubility was measured by the method described above, and that samples dissolved 24 hours after adding 20.0 g to 100 g of desalinated water, were evaluated as "20 g <", and samples of which 0 , 05 g dissolved in 100 g of desalinated water 1.00 g but did not dissolve were evaluated as 0.05-1.00 g.
[0307] To obtain the melting point, "<45" indicates a melting point below 45 ° C.
[0308] The skin contact surface of the top sheet of the sanitary napkin was coated with the aforementioned blood modifying agent. Each blood modifying agent was used directly, when the blood modifying agent was liquid at room temperature or when the blood modifying agent was solid at room temperature, it heated to its melting point of 20 ° C, and a HMA seam control gun was used for atomizing the blood modifying agent and coating on the skin contact surface of the top sheet at a base weight of about 5 g / m2. - FIG. 1 is a view of Example 1, showing the region of the top sheet that contains the blood modifying agent. As shown in FIG. 1, almost the entire surface of the top sheet 2 of the sanitary napkin 1 in Example 1 is the blood modifying region containing agent 4 comprising the blood modifying agent. In fig. 1, numeral 3 denotes a stamped section (groove or depression). - FIG. 2 is an electron micrograph of the skin contact surface of a topsheet on a sanitary napkin (No. 5), where the topsheet comprises C2L oil tri-glycerides of fatty acids. As clearly seen in the figure. 2, tri-C2L oil fatty acid glycerides are present on the surfaces of the fibers as fine particles. [Test methods]
[0309] An acrylic plate with an open hole (200 mm x 100 mm, 125 g, with 40 mm x 10 mm open hole in the center) was placed on a top sheet comprising each blood modifying agent, and 3 g horse blood at EDTA 37 ± 1 ° C
[0310] (Obtained by the addition of ethylenediaminetetraacetic acid
[0311] (Hereinafter "EDTA") for horse blood to prevent clotting) was withdrawn through the hole with a pipette (Once), and after 1 minute, 3 g of blood horse with EDTA, at 37 ± 1 ° C, it was added dropwise through the acrylic plate orifice, with a pipette (twice).
[0312] After the second blood drop, the acrylic plate was immediately removed and 10 sheets of filter paper (Advantec Toio Kaisha, Ltd, qualitative filter paper No.2, 50 mm x 35 mm) were placed in the place where the blood had been spilled, and then an overover weight was placed at a pressure of 30 g / cm2. After 1 minute, the filter paper was removed and the "rewet rate" was calculated using the following formula. Reheat Rate (%)
[0313] = 100 x (mass of filter paper after testing - mass of initial filter paper) / 6 In addition to the re-wetting rate assessment, the "absorbent body migration rate" was also measured as the time until migration of blood from the top sheet to the absorbent body after the second blood drop. The migration rate of the absorbent body is the time from introducing the blood on the top sheet, until the redness of the blood can be seen on the surface and inside the top sheet.
[0314] The results of the rewetting rate and the absorbent body migration rate are shown below in Table 2.
[0315] The whiteness of the skin contact surface of the top sheet, after the absorption body migration rate test was assessed visually, on the next scale.
[0316] VG (Veri Good): There is practically no redness of the remaining blood, and no clear delimitation between areas with and without blood.
[0317] G (Good): slight redness of blood remaining, but it is difficult to delineate between areas with and without blood.
[0318] F (Fair): slight redness of remaining blood, discernible bloody areas.
[0319] P (Poor): redness of the blood completely left. The results are summarized below in Table 2. Table 2


[0320] In the absence of a blood modifying agent, the wetting rate was 22.7% and the migration rate of the absorbent body was greater than 60 seconds, but the glycerin and fatty acid triesters produced at all rewetting rates not exceeding 7.0% and the absorbent body migration rates not more than 8 seconds, and therefore significantly improves the absorption performance. Of glycerin and fatty acid triesters, however, no major improvement in absorption performance was seen with NA50 which had a melting point above 45 ° C.
[0321] Likewise, the absorption performance has also been significantly improved with blood modifying agents that have an IOB of about 0-0.60, a melting point of no more than about 45 ° C, a solubility in water of about 0.00-0.05 g in 100 g of water at 25 ° C, and an average molecular weight by weight of less than about 1,000.
[0322] Then, several volunteer subjects were invited to use sanitary napkins No. 1-47, and the responses obtained indicate that sanitary napkins comprising blood-modifying agents No. 1-22, the top sheets had none. sticky feeling and the upper leaves were smooth, even after absorption of menstrual blood. The responses also indicated that the differences were notable with sanitary napkins No. 23, 29, 34, 45 and 47.
[0323] In addition, with No. 1 to 22 sanitary napkins and in particular with sanitary napkins that compound blood modifying agents Nos. 1-11, 15-19 and 22, the skin contact surfaces of the upper leaves after the absorption of menstrual blood had not been reddened by the blood and the discomfort was minimal. [Example 2]
[0324] The rate of rewetting was assessed for blood from different animals. Then, the blood was used for the assay. [Animal species] (1) Human (2) Horse (3) Sheep [Blood types] • defibrinated blood: collection of blood and stirred together with glass beads in an Erlenmeier of approximately 5 minutes. • Blood EDTA: 65 mL of venous blood with the addition of 0.5 mL of a 12% isotonic sodium chloride solution of 12% EDTA. [Fractionation]
[0325] Blood serum or plasma: The supernatant obtained after centrifuging defibrinated blood or blood with EDTA for 10 minutes at room temperature at about 1900 G.
[0326] Blood cells: obtained by removing serum from the blood, washing twice with phosphate buffered saline (PBS), and adding phosphate buffered saline with the portion removed from the serum.
[0327] An absorbent article was produced in the same manner as in Example 1, except that the tri-C2L fatty acid glyceride oil was coated with a base weight of about 5 g / m2, and the rewetting rate of each of the referred blood samples was evaluated. The measurement was performed three times for each blood sample, and the average value was recorded.
[0328] The results are shown in Table 3 below. Table 3

[0329] The same trend was observed with human and sheep blood as blood with horse EDTA, as obtained in Example 1. A similar trend was also observed with defibrinated blood and EDTA blood.
[0330] [Example 3]
[0331] [Evaluation of blood retention]
[0332] Blood retention was assessed by a topsheet comprising a blood modifying agent and a topsheet comprising no blood modifying agents.
[0333] [Test methods] (1) A tri-C2L fatty acid glyceride oil was atomized on the skin contact surface of a top sheet formed from an air device through the nonwoven fabric ( fiber composite composed of polyester and polyethylene terephthalate, base weight: 35 g / m2), using a HMA seam control gun, for coating a base weight of about 5 g / m2. For comparison, an uncoated sheet was also prepared with tri-C2L fatty acid glyceride oil. In addition, both the top coated tri-C2L fatty acid glyceride oil sheet and the uncoated top sheet were cut to a size of 0.2 g, and the mass (a) of the cell filter + top sheet was measured with precision. (2) After adding about 2 ml of EDTA horse blood from the side of the skin contact surface, which was left to stand for 1 minute. (3) The cell filter was placed in a centrifuge tube, and rotated downwards to remove excess blood horse with EDTA. (4) The mass (b), of the top sheet containing the cell filter, was measured + blood horse with EDTA. (5) The initial absorption (g) per 1 g of top sheet was calculated using the following formula.
[0334] Initial absorption = [mass (b) - mass (a)] / 0.2
[0335] (6) The cell filter was again established in the
[0336] centrifuge tube and centrifuged at room temperature for 1 minute, at about 1200 G. (7) The mass (c), the first sheet containing the cell filter was measured + blood horse with EDTA.
[0337] (8) Post-test absorption (g) per 1 g of top sheet was calculated using the following formula.
[0338] After the absorption test = [mass (c) - mass (a)] / 0.2
[0339] (9) Blood retention (%) was calculated according to the following formula.
[0340] Blood retention (%) = 100 x post-test
[0341] initial absorption / absorption
[0342] The measurement was performed 3 times, and the average value was recorded.
[0343] The results are shown in Table 4 below. Table 4

[0344] The top sheets that comprise blood-modifying agents had low blood retentions, suggesting that the blood migrated quickly to the absorbent body after absorption. [Example 4]
[0345] [Viscosity of blood modifying agent containing blood]
[0346] Blood viscosity by modifying blood containing agent was measured using a Rheometric
[0347] ARES Expansion System (Rheometric Scientific, Inc.).
[0348] After the addition of 2% by mass of PANACET 810S for defibrinated blood horse, the mixture was gently stirred to form a sample, the sample was placed on a 50 mm diameter plate, with an interval of 100 μπi, and viscosity was measured at 37 ± 0.5 ° C. The sample was not subjected to a uniform cutting speed, due to the parallel plate, but the average shear rate indicated by the device was 10 s -1.
[0349] The viscosity of defibrinated horse blood containing 2 wt% PANACET 810S was 5.9 mPa-s, while the viscosity of defibrinated horse blood containing no blood modifying agent was 50.4 mPa-s. Thus, defibrinated horse blood containing 2% by mass PANACET 810S clearly had a viscosity of approximately 90% less than blood containing no blood modifying agent.
[0350] It is known that blood contains components, such as blood cells and has thixotropy, and it has been found that the blood modifying agent of the present disclosure, can reduce blood viscosity in the low viscosity range.
[0351] The reduction in blood viscosity, presumably, allows the menstrual blood absorbed to migrate quickly from the upper sheet to the absorbent body. [Example 5]
[0352] [Photomicrograph of blood modifying blood containing the agent]
[0353] Menstrual blood was sampled from healthy volunteers in food wrap film, and PANACET 810S dispersed in a 10-fold mass of phosphate buffer was added to a portion of it at a concentration of 810S PANACET 1% by mass. Menstrual blood was dropped on a glass slide, a cover glass was placed thereover, and the condition of the erythrocytes was observed with an optical microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 3 (a), and a photomicrograph of menstrual blood containing PANACET 810S is shown in FIG. 3 (b).
[0354] As shown in FIG. 3 (a), it appears that the erythrocytes formed aggregates, such as, rolls in the menstrual blood containing no blood modifying agent, whereas, as shown in Fig. 3 (b), the erythrocytes were stably dispersed in the menstrual blood containing PANACET 810S. This suggests that the blood modifying agent functions to stabilize erythrocytes in the blood. [Example 6]
[0355] [The surface tension of blood-modifying agent containing blood]
[0356] The surface tension of the blood, containing a blood modifying agent was measured by the droplet method, using a Master500 drop contact angle meter by Kiowa Interface Science Co., Ltd. The surface tension was measured after the addition of a prescribed amount of blood-modifying agent for defibrinated and shaking sheep's blood.
[0357] The measurement was performed automatically with a device, and the Y density was determined by the following formula (see Fig. 4.).
[0358] i = gxpx (de) 2 xl / H
[0359] g: constant gravitational
[0360] 1 / H: The correction factor determined from ds / d: Density of: Maximum diameter
[0361] ds: Diameter at the edge location of falling edge
[0362] The density of p was measured at the temperatures indicated in Table 5, according to JIS K 2249-1995, "and the density / mass density / volume test methods of conversion tables", "5. Vibratory density test method ".
[0363] The measurement was performed using a 505 promoter by Kioto Electronics Co., Ltd.
[0364] The results are shown in Table 5 below. Table 5

[0365] Table 5 shows that the blood modifying agent can decrease the surface tension of the blood, despite its very low water solubility, as seen by a water solubility of 0.00-0.05 g in 100 g of water at 25 ° C.
[0366] Reducing the surface tension of the blood, presumably, allows the blood to migrate rapidly absorbed from the top sheet to the absorbent body, without being trapped between the top sheet fibers.
[0367] This disclosure relates to the following J1 to J8. [J1]
[0368] An absorbent article comprising a liquid-permeable top sheet, a liquid-impermeable back sheet and an absorbent body between the liquid-permeable top sheet and a liquid-impermeable back sheet, wherein the liquid-permeable top sheet comprises a blood modifying agent with an IOB of 0.00-0.60, a melting point of not more than 45 ° C, a water solubility of 0.00-0.05 g in 100 g of water at 25 ° C , and an average molecular weight below 1,000. [J2]
[0369] The absorbent article according to Jl, in which the blood modifying agent is selected from the group consists of the following items (i) - (iii), and any combinations thereof: (i) a hydrocarbon; (ii) a compound that has (ii-1) a hydrocarbon fraction, and (ii-2) one or more groups, the same or different, selected from the group consisting of a carbonyl group (-CO-) and a group oxy (-0-) inserted between a single DC connection of the hydrocarbon unit; and (iii) a compound having (iii-1) a hydrocarbon radical, (iii-2) one or more the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (- 0-) inserted between a single CC bond of the hydrocarbon unit, and (iii-3) one or more groups, the same or different, selected from the group consisting of carboxyl groups (-COOH) and a hydroxyl group (-OH ), replacing a hydrogen atom of the hydrocarbon moiety, with the proviso that when two or more oxy groups are inserted into the compound of (ii) or (iii), the oxy groups are not adjacent. [J3]
[0370] The absorbent article according to J1 or J2, in which the blood modifying agent is selected from the group consisting of the following items: (i ') - (iii), and any combination thereof: (i' ) a hydrocarbon; (ii ') a compound having (ii'-1, a hydrocarbon radical, and (ii'-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (-CO-) , bonding ester (-COO-), bonding carbonate (-COO-) and ether bonding (-0-) inserted between a single CC bonding of the hydrocarbon fraction; and (iii ') a compound that has (iii'- 1), a hydrocarbon radical, (iii '-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO-), and ether bond (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii'-3) one or more identical or different groups selected from the group consisting of the carboxyl group (- COOH), and a hydroxyl group (-OH) replacing a hydrogen atom in the hydrocarbon radical, with the proviso that when two or more equal or different bonds are inserted in the compound of (ii) or ( iii 1), the connections are not adjacent. [J4]
[0371] The absorbent article according to any one of J1 to J3, in which the blood modifying agent is selected from the group consisting of the following items (A) - (F), and any combination thereof: (A) an ester of (A1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical, and (A2) a compound • having a chain hydrocarbon moiety and a carboxyl group with a hydrogen atom replacing the chain hydrocarbon radical; (B) an ether of (B1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (B2), a compound having a chain hydrocarbon radical and a group hydroxyl, replacing a hydrogen atom in the hydrocarbon radical chain; (C) an ester of (C1) a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a hydrocarbon radical chain and 2-4 carboxyl groups, replacing hydrogen atoms in the hydrocarbon radical e (C2), a compound having a chain hydrocarbon radical and a hydroxyl group, replacing a hydrogen atom in the chain hydrocarbon radical; (D) a compound having a chain hydrocarbon radical and a bond selected from the group consisting of an ether bond (-0-), the carbonyl bond (-CO-), ester bond (-COO-) and bonding carbonate (-OCOO-) inserted between a single DC link of the chain hydrocarbon unit; (E) a C3-C6-glycol polyoxy, or alkyl ester or alkyl ether, and (F) a chain hydrocarbon. [J5]
[0372] The absorbent article according to any one of J1 to J4, in which the blood modifying agent is selected from the group consisting of (a1) an ester of a tetraol hydrocarbon chain and at least one fatty acid, ( a2) an ester of a chain hydrocarbon triol and at least one fatty acid, (a3) an ester of a diol chain hydrocarbon and at least one fatty acid, (b1) an ether of a tetraol chain hydrocarbon and at minus an aliphatic monofunctional alcohol, (b2) a chain hydrocarbon triol ether and at least one aliphatic monofunctional alcohol, (b3) a diol chain hydrocarbon ether and at least one monohydrous aliphatic alcohol, (c1) one ester of a hydrocarbon chain tetracarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with carboxyl groups, and at least one aliphatic monohydric alcohol, (c2) an ester of a hydrocarbon-tricarboxylic acid, hydroxy, alkoxy or oxoacid acid with 3 group s carboxyl, and at least one monohydric aliphatic alcohol, (c3) an ester of a hydrocarbon, hydroxy, alkoxy or oxoacid chain dicarboxylic acid with two carboxyl groups, and at least one monofunctional alcohol, (d1) an ether of one aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d2) a dialkyl ketone, (d3) an ester of a fatty acid and an aliphatic monohydric alcohol, (d4) a dialkyl carbonate, (e1) a C3-C6 polyoxy glycol, (e2) an ester of a polyoxy-C3-C6 alkylene glycol and at least one fatty acid, (e3) a polyoxy C3-C6 alkylene glycol ether and at least one aliphatic monohydric alcohol, and (f1) an alkane of chain, and any combination thereof. [J6]
[0373] The absorbent article according to any one of J1 and J5, in which the blood modifying agent has a vapor pressure of 0.00-0.01 Pa, in an atmosphere, at 40 ° C. [J7]
[0374] The absorbent article according to any one of J1 to J6, in which the blood modifying agent has an average molecular weight in weight not exceeding 900. [J8]
[0375] The absorbent article according to any one of J1 and J7, wherein the liquid-permeable top sheet is a nonwoven or woven fabric, and - the blood modifying agent is attached to the fiber surfaces of the fabric not woven or woven. [J9]
[0376] The absorbent article according to any of J1 to J8, which is a hygienic absorbent or protector for panties.
[0377] This application claims the benefits of Japanese Application No. 2011-079446 and No. 2011-192144 entire disclosures of which are hereby incorporated by reference. References List of Signs 1 Hygienic absorbent 2 Top sheet 3 Stamped section 4 Region containing blood modifying agent.

权利要求:
Claims (8)
[0001]
1. ABSORBENT ARTICLE ”, and comprising a liquid-permeable top sheet, a liquid-impermeable back sheet and an absorbent body between the liquid-permeable top sheet and the liquid-impermeable back sheet, characterized in that the liquid-permeable top sheet comprises a blood modifying agent with an IOB of 0.00-0.60, a melting point of not more than 45 ° C, a water solubility of 0.00-0.05 g in 100 g of water at 25 ° C , and an average molecular weight below 1,000.
[0002]
2. ABSORBENT ARTICLE ”, according to claim 1, characterized in that the blood modifying agent is selected from the group consisting of the following items: (i) - (iii), and any combination thereof: (i) a hydrocarbon , (ii) a compound that has (ii-1) a hydrocarbon fraction, and (ii-2) one or more groups, the same or different, selected from the group consisting of a carbonyl group (-CO-) and one oxy group (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii) a compound that has (iii-1) a hydrocarbon radical, (iii-2) one or more identical or different groups selected from of the group consisting of a carbonyl group (-CO-) and an oxy group (-0-) inserted between a single CC bond of the hydrocarbon unit, and (iii-3) one or more groups, the same or different, selected from among the group consisting of carboxyl groups (-COOH) and a hydroxyl group (-OH), replacing a hydrogen atom of the hydrocarbon portion, with the proviso that when two or more oxy groups are inserted into the compound of (ii) or (iii), the oxy groups are not adjacent.
[0003]
3. ABSORBENT ARTICLE ”, according to any one of the preceding claims, characterized in that the blood modifying agent is selected from the group consisting of the following items: (i ') - (iii), and any combination thereof: ( i ') a hydrocarbon, (ii') a compound having (ii'-1), a hydrocarbon radical, and (ii'-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (-CO-), bonding ester (-COO-), bond carbonate (-OCOO-) and ether bond (-0-) inserted between a single CC bond of the hydrocarbon fraction, and (ii-1) a compound having (iii'-l), a hydrocarbon radical, (iii '-2) one or more, the same or different titles, selected from the group consisting of carbonyl bond (-CO-), ester bond (-COO -), carbonate bond (-OCOO-), and ether bond (-0-) inserted between a single DC bond of the hydrocarbon unit, and (iii '-3) one or more identical or different groups selected s from the group consisting of the carboxyl group (-COOH) and a hydroxyl group (-OH) replacing a 'hydrogen in the hydrocarbon radical; with the proviso that when two or more equal or different obligations are inserted into the compound of (ii 1) or (iii 1), the bonds are not adjacent.
[0004]
4. "ABSORBENT ARTICLE" according to any one of the preceding claims, characterized in that the blood modifying agent is selected from the group consisting of the following items (A) - (F), and any combination thereof (A) one ester of (A1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical, and (A2), a compound having a chain hydrocarbon radical and a carboxyl group replacing one hydrogen atom over the hydrocarbon chain fraction; (B) an ether of (B1), a compound having a chain hydrocarbon radical and 2-4 hydroxyl groups, replacing hydrogen atoms in the chain hydrocarbon radical and (B2), a compound having a chain hydrocarbon radical and a group hydroxyl, replacing a hydrogen atom in the hydrocarbon fraction chain, (C) an ester of (C1) a carboxylic acid, hydroxy acid, alkoxy or oxoacid acid comprising a radical hydrocarbon chain and 2-4 carboxyl groups, replacing atoms hydrogen in the chain hydrocarbon radical e (C2), a compound having a chain hydrocarbon radical and a hydroxyl group, replacing a hydrogen atom in the chain hydrocarbon radical; (D) a compound having a chain hydrocarbon radical and a bond selected from the group consisting of an ether bond (-O-), the carbonyl bond (-CO-), ester bond (-COO-) and bonding carbonate (-OCOO-) inserted between a single DC link of the chain hydrocarbon unit; (E), a polyoxy-C3-C6 alkylene glycol, or alkyl ester or alkyl ether, and (F) a chain hydrocarbon.
[0005]
5. "ABSORBENT ARTICLE" according to any one of the preceding claims, characterized in that the blood modifying agent is selected from the group consisting of (a1) an ester of a tetraol chain hydrocarbon and at least one fatty acid, ( a2) an ester of a chain hydrocarbon triol and at least one fatty acid, (a3) an ester of a diol chain hydrocarbon and at least one fatty acid, (B1) an ether of a tetraol chain hydrocarbon and at minus an aliphatic monofunctional alcohol, (b2) a hydrocarbon chain triol ether, and at least one aliphatic monofunctional alcohol, (b3) a diol chain hydrocarbon ether and at least one aliphatic monohydric alcohol, (c1) an ester of a hydrocarbon chain tetracarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with 4 carboxyl groups, and at least one aliphatic monohydric alcohol, (c2) an ester of a tricarboxylic acid hydrocarbon chain, hydroxy acid, alcohol xi or oxoacid acid with 3 carboxyl groups, and at least one aliphatic monohydric alcohol, (C3), an ester of a hydrocarbon chain dicarboxylic acid, hydroxy acid, alkoxy or oxoacid acid with two carboxyl groups, and at least one alcohol aliphatic monohydric, (d1) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d2) a dialkyl ketone, (d3) an ester of a fatty acid and an aliphatic monohydric alcohol, (d4) a carbonate of dialkyl, (ei) a C3-C6 polyoxy, alkylene glycol, (e2) an ester of a C3-C6 polyoxy, alkylene glycol and at least one fatty acid, (e3) an ether of a C3-C6 polyoxy, alkylene glycol and at least one aliphatic monofunctional alcohol, and (f1) an alkane chain, or any combination thereof.
[0006]
6. "ABSORBENT ARTICLE" according to any one of the preceding claims, characterized in that the blood modifying agent has a vapor pressure of 0.00-0.01 Pa, in an atmosphere, at 40 ° C.
[0007]
7. "ABSORBENT ARTICLE" according to any one of the preceding claims, characterized in that the blood modifying agent has an average molecular weight in weight not exceeding 900.
[0008]
8. "ABSORBENT ARTICLE" according to any one of the preceding claims, characterized in that the liquid-permeable topsheet is a nonwoven or woven fabric, and the blood-modifying agent is attached to the fiber surfaces of the nonwoven fabric or fabric.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112013024052B1|2021-03-09|absorbent article

---

US9339423B2|2016-05-17|Absorbent article

---

ES2702377T3|2019-02-28|Absorbing article

---

TWI551273B|2016-10-01|Absorbent items

---

TWI577350B|2017-04-11|Absorbent items

---

US9375365B2|2016-06-28|Absorbent article

---

US20150065978A1|2015-03-05|Absorbent article

---

US9498387B2|2016-11-22|Absorbent article having bent sections

---

US9770526B2|2017-09-26|Absorbent article

---

EP2701654A1|2014-03-05|Absorbent article

---

AU2013321211B2|2016-07-28|Absorbent article

---

WO2013047864A1|2013-04-04|Absorbent article

---

WO2013047866A1|2013-04-04|Absorbent Article

---

WO2013047888A1|2013-04-04|Absorbent article

---

TWI573573B|2017-03-11|Absorbent items

---

WO2013047868A1|2013-04-04|Absorbent Article, Top Sheet For Absorbent Article and Method For Producing Top Sheet

同族专利:

---

公开号 | 公开日

---

ES2749576T3|2020-03-23|

---

CN102844005B|2014-05-07|

---

ES2655174T3|2018-02-19|

---

KR101389215B1|2014-04-24|

---

AR085730A1|2013-10-23|

---

EA030207B1|2018-07-31|

---

EP2691061A4|2014-10-22|

---

EA201300952A1|2014-03-31|

---

MY161432A|2017-04-14|

---

BR112013024052A2|2016-12-13|

---

EA201800163A2|2018-07-31|

---

EP3295910A1|2018-03-21|

---

JP2013063245A|2013-04-11|

---

JP5122007B1|2013-01-16|

---

WO2012133724A1|2012-10-04|

---

JP5836883B2|2015-12-24|

---

TWI448277B|2014-08-11|

---

AU2012233342A1|2013-10-17|

---

JP2013063247A|2013-04-11|

---

EP3295910B1|2019-09-11|

---

EA036106B1|2020-09-29|

---

EP2691061B1|2017-10-18|

---

EP2691061A1|2014-02-05|

---

CN103735369A|2014-04-23|

---

AU2012233342B2|2014-03-13|

---

US10543132B2|2020-01-28|

---

TW201302175A|2013-01-16|

---

EA201800163A3|2019-03-29|

---

CN102844005A|2012-12-26|

---

US20140358102A1|2014-12-04|

---

KR20130133048A|2013-12-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

JPS593110B2|1974-08-20|1984-01-23|Itsuki Ban|

---

US3929135A|1974-12-20|1975-12-30|Procter & Gamble|Absorptive structure having tapered capillaries|

---

JPS5717081A|1981-05-25|1982-01-28|Noriko Ikegami|Electronic interpreter|

---

US4588630A|1984-06-13|1986-05-13|Chicopee|Apertured fusible fabrics|

---

DE3852732T2|1987-07-30|1995-05-24|Kao Corp|Sanitary ware.|

---

JPH0775616B2|1987-07-30|1995-08-16|花王株式会社|Surface material for sanitary goods|

---

US4759754A|1987-08-26|1988-07-26|Personal Products Company|Sanitary napkin|

---

JPH082364B2|1987-12-16|1996-01-17|花王株式会社|Sanitary goods surface materials|

---

JPH022104A|1988-06-15|1990-01-08|Canon Inc|Mask holder|

---

JPH0720856B2|1988-12-01|1995-03-08|株式会社大塚製薬工場|Composition for sterilizing and cleaning skin|

---

JP2728921B2|1989-03-01|1998-03-18|花王株式会社|Method for producing nonwoven fabric having irregularities|

---

JPH03262172A|1990-03-12|1991-11-21|Omron Corp|Optical circuit component assembling jig|

---

SK37993A3|1991-07-23|1993-10-06|Procter & Gamble|Method of making curved, shaped absorbent article|

---

US5334176A|1991-07-23|1994-08-02|The Procter & Gamble Company|Absorbent core for use in catamenial products|

---

MA22660A1|1991-10-01|1993-04-01|Procter & Gamble|ABSORBENT ARTICLE COMPRISING FLAPS AND DIFFERENTIAL EXTENSIBILITY AREAS.|

---

JP3091283B2|1991-12-09|2000-09-25|花王株式会社|Sanitary napkin|

---

JPH065614A|1992-06-17|1994-01-14|Murata Mfg Co Ltd|Heat treatment device|

---

EP0699063A1|1993-05-21|1996-03-06|The Procter & Gamble Company|Absorbent article having anti-wicking crimp seal|

---

JPH0784697A|1993-09-10|1995-03-31|Canon Inc|Information processor|

---

US5614283A|1994-12-22|1997-03-25|Tredegar Industries|Absorbent composite with three-dimensional film surface for use in absorbent disposable products|

---

JP2974934B2|1995-06-02|1999-11-10|ザ、プロクター、エンド、ギャンブル、カンパニー|Sanitary napkin|

---

US5891126A|1996-08-30|1999-04-06|The Procter & Gamble Company|Absorbent interlabial device treated with a polysiloxane emollient|

---

US5650214A|1996-05-31|1997-07-22|The Procter & Gamble Company|Web materials exhibiting elastic-like behavior and soft, cloth-like texture|

---

JPH1095810A|1996-09-24|1998-04-14|Oji Paper Co Ltd|High water absorption resin and production thereof|

---

US6156024A|1996-12-03|2000-12-05|The Procter & Gamble Company|Absorbent articles having lotioned leg cuffs|

---

ZA985679B|1997-06-30|1999-01-26|Procter & Gamble|Absorbent article with multi-layered extensible wings|

---

US6458112B1|1997-12-05|2002-10-01|The Procter & Gamble Company|Compound sanitary napkin having flaps and zone of extensibility|

---

US6262331B1|1998-06-05|2001-07-17|The Procter & Gamble Company|Absorbent article having a topsheet that includes selectively openable and closable openings|

---

US6730819B1|1999-03-05|2004-05-04|The Procter & Gamble Company|Articles comprising oxidizing and hemolytic agents|

---

EP1034804A1|1999-03-05|2000-09-13|The Procter & Gamble Company|Articles comprising an oxidising agent and a hemolytic agent|

---

US6153209A|1999-09-28|2000-11-28|The Procter & Gamble Company|Article having a transferable breathable skin care composition thereon|

---

JP3748743B2|1999-10-04|2006-02-22|ユニ・チャーム株式会社|Absorbent article and manufacturing method thereof|

---

JP3611761B2|1999-11-02|2005-01-19|花王株式会社|Absorbent articles|

---

US20010044614A1|1999-12-23|2001-11-22|Damay Emmanuelle Cecile|Reducing agents for feminine care products|

---

JP3498035B2|2000-03-07|2004-02-16|ユニ・チャーム株式会社|Multilayer absorbent material for hygiene articles|

---

JP3701208B2|2000-03-13|2005-09-28|ユニ・チャーム株式会社|An apertured sheet, an absorbent article using the apertured sheet, and a method for producing the apertured sheet.|

---

US6939553B2|2000-09-11|2005-09-06|Kimberly-Clark Worldwide, Inc.|Treated substrate with improved transfer efficiency of topical application|

---

US6548732B2|2001-03-23|2003-04-15|Paragon Trade Brands, Inc.|Absorbent article having hydrophobic leak protection zones|

---

ES2338297T3|2001-04-17|2010-05-06|THE PROCTER &amp; GAMBLE COMPANY|AN ABSORBENT ARTICLE UNDERSTANDING AN AGENT ABLE TO PROVIDE A PERCEPTION TO THE USER.|

---

JP4596506B2|2001-07-02|2010-12-08|ユニ・チャーム株式会社|Absorbent articles and lotions for absorbent articles|

---

JP3926587B2|2001-07-12|2007-06-06|ユニ・チャーム株式会社|Absorbent articles|

---

JP4855606B2|2001-08-10|2012-01-18|ユニ・チャーム株式会社|Absorbent articles|

---

SE519783C2|2001-08-31|2003-04-08|Sca Hygiene Prod Ab|Absorbent articles including apertures in the absorbent body|

---

US20030082219A1|2001-10-01|2003-05-01|The Procter & Gamble Company|Skin care compositions comprising low concentrations of skin treatment agents|

---

SG103382A1|2002-01-11|2004-04-29|Uni Charm Corp|Colored absorbent article|

---

JP4278963B2|2002-03-26|2009-06-17|ユニ・チャーム株式会社|Absorbent articles|

---

JP4693847B2|2002-03-26|2011-06-01|ユニ・チャーム株式会社|Absorbent article and manufacturing method thereof|

---

US8053626B2|2002-06-12|2011-11-08|Sca Hygiene Products Ab|Absorbent article containing a skincare composition and method of making and using same|

---

AT426417T|2002-06-12|2009-04-15|Sca Hygiene Prod Ab|ABSORBENT ARTICLE WITH A SKIN CARE COMPOSITION|

---

JP3091283U|2002-07-08|2003-01-24|士維 黄|Kick board connecting rod type vibration prevention structure|

---

JP3949020B2|2002-07-19|2007-07-25|花王株式会社|Absorbent articles|

---

US9035123B2|2002-10-01|2015-05-19|The Procter & Gamble Company|Absorbent article having a lotioned topsheet|

---

US8030535B2|2002-12-18|2011-10-04|The Procter & Gamble Company|Sanitary napkin for clean body benefit|

---

JP2005095759A|2003-09-24|2005-04-14|San-Dia Polymer Ltd|Absorbent and absorbing article comprising the absorbent|

---

US20050096614A1|2003-10-29|2005-05-05|Perez Roberto C.|Cover layer for an absorbent article|

---

JP4476102B2|2003-12-11|2010-06-09|花王株式会社|Absorbent article surface sheet|

---

PL1778146T3|2004-06-21|2017-06-30|The Procter And Gamble Company|Absorbent article with lotion-containing topsheet|

---

JP4459013B2|2004-10-20|2010-04-28|花王株式会社|Absorbent articles|

---

US8211078B2|2005-02-17|2012-07-03|The Procter And Gamble Company|Sanitary napkins capable of taking complex three-dimensional shape in use|

---

JP4799012B2|2005-03-10|2011-10-19|株式会社資生堂|Oily solid cosmetics|

---

JP4514630B2|2005-03-16|2010-07-28|花王株式会社|Absorbent article surface sheet|

---

JP4523866B2|2005-03-31|2010-08-11|ユニ・チャーム株式会社|Absorbent articles|

---

US8481806B2|2005-06-02|2013-07-09|The Procter And Gamble Company|Absorbent article having traverse reinforcing element|

---

JP4792249B2|2005-07-11|2011-10-12|ユニ・チャーム株式会社|Body fluid absorbent article|

---

JP2006233405A|2005-08-16|2006-09-07|Asahi Kasei Chemicals Corp|Fiber treatment agent|

---

KR100996044B1|2005-08-25|2010-11-22|더 프록터 앤드 갬블 캄파니|Absorbent article comprising condensed tannin|

---

DE102005060461A1|2005-12-17|2007-07-12|Paul Hartmann Ag|Medical composition|

---

CN101400329B|2006-03-14|2014-02-19|宝洁公司|Absorbent articles with lotions|

---

US8221774B2|2006-06-12|2012-07-17|The Procter & Gamble Company|Lotioned wipe product to reduce adhesion of soils or exudates to the skin|

---

JP5069891B2|2006-06-23|2012-11-07|ユニ・チャーム株式会社|Non-woven|

---

JP5328089B2|2006-06-23|2013-10-30|ユニ・チャーム株式会社|Multilayer nonwoven fabric and method for producing multilayer nonwoven fabric|

---

JP5123497B2|2006-06-23|2013-01-23|ユニ・チャーム株式会社|Nonwoven fabric, nonwoven fabric manufacturing method and nonwoven fabric manufacturing apparatus|

---

JP5123513B2|2006-06-23|2013-01-23|ユニ・チャーム株式会社|Absorber|

---

JP5328088B2|2006-06-23|2013-10-30|ユニ・チャーム株式会社|Non-woven|

---

JP5123512B2|2006-06-23|2013-01-23|ユニ・チャーム株式会社|Non-woven|

---

JP5123511B2|2006-06-23|2013-01-23|ユニ・チャーム株式会社|Non-woven|

---

JP5123505B2|2006-06-23|2013-01-23|ユニ・チャーム株式会社|Non-woven|

---

JP5069890B2|2006-06-23|2012-11-07|ユニ・チャーム株式会社|Non-woven|

---

JP5154048B2|2006-06-23|2013-02-27|ユニ・チャーム株式会社|Non-woven|

---

US8304600B2|2006-06-23|2012-11-06|Uni-Charm Corporation|Absorbent article|

---

WO2008004463A1|2006-07-05|2008-01-10|Kao Corporation|Absorbent article|

---

JP5021380B2|2006-07-05|2012-09-05|花王株式会社|Absorbent articles|

---

JP4980685B2|2006-09-29|2012-07-18|大王製紙株式会社|Absorbent articles|

---

JP4939192B2|2006-12-05|2012-05-23|ユニ・チャーム株式会社|Nonwoven fabric, method for producing nonwoven fabric, and absorbent article|

---

EP2090683B1|2006-12-05|2011-10-12|Uni-charm Corporation|Nonwoven fabric, process for production of nonwoven fabric and absorbent articles|

---

JP4939196B2|2006-12-12|2012-05-23|ユニ・チャーム株式会社|Nonwoven fabric, method for producing nonwoven fabric, and absorbent article|

---

EP2092918A4|2006-12-13|2012-06-27|Uni Charm Corp|Absorbent article|

---

AR065378A1|2007-02-16|2009-06-03|Procter & Gamble|ABSORBENT ARTICLE WITH LOTION THAT INCLUDES A POLYPROPYLENE GLYCOL MATERIAL|

---

JP4979423B2|2007-03-20|2012-07-18|花王株式会社|Absorbent articles|

---

JP4979424B2|2007-03-20|2012-07-18|花王株式会社|Absorbent articles|

---

JP4986673B2|2007-03-27|2012-07-25|花王株式会社|Absorbent articles|

---

JP4879074B2|2007-04-17|2012-02-15|ユニ・チャーム株式会社|Nonwoven fabric manufacturing method|

---

US8273941B2|2007-04-17|2012-09-25|Uni-Charm Corporation|Nonwoven fabric, method for producing nonwoven fabric, and absorbent article|

---

JP5114087B2|2007-04-17|2013-01-09|ユニ・チャーム株式会社|Nonwoven fabric and absorbent article|

---

EP1992367B1|2007-05-15|2012-06-27|The Procter & Gamble Company|Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin|

---

EP1992366B1|2007-05-15|2011-07-06|The Procter & Gamble Company|Use of a lotion composition on an absorbent article for reducing adherence of feces or menses to the skin|

---

JP5161491B2|2007-05-30|2013-03-13|ユニ・チャーム株式会社|Absorbent articles|

---

JP5568210B2|2007-06-13|2014-08-06|ユニ・チャーム株式会社|Non-woven sheet manufacturing method|

---

JP5497987B2|2007-06-22|2014-05-21|ユニ・チャーム株式会社|Nonwoven fabric and method for producing the same|

---

JP2009005767A|2007-06-26|2009-01-15|Kao Corp|Absorbent article|

---

US20090030391A1|2007-07-25|2009-01-29|John Lee Hammons|Absorbent article|

---

JP4652387B2|2007-10-03|2011-03-16|王子製紙株式会社|Absorber product with folded part|

---

US8178748B2|2008-02-15|2012-05-15|The Procter & Gamble Company|Absorbent article|

---

US20090221978A1|2008-02-15|2009-09-03|Joseph Anthony Gatto|Absorbent article with lotion comprising a polypropylene glycol material|

---

JP2009201878A|2008-02-29|2009-09-10|Uni Charm Corp|Absorbent article|

---

JP5173616B2|2008-06-10|2013-04-03|花王株式会社|Absorbent articles|

---

JP5371361B2|2008-10-10|2013-12-18|ユニ・チャーム株式会社|Absorbent article and method for manufacturing absorbent article|

---

JP5455363B2|2008-12-25|2014-03-26|ユニ・チャーム株式会社|Thin absorbent article|

---

JP5520124B2|2009-05-14|2014-06-11|ユニ・チャーム株式会社|Liquid permeable non-woven fabric|

---

RU2555615C2|2009-05-20|2015-07-10|Као Корпорейшн|Absorbing body and absorbing product|

---

JP5401177B2|2009-06-04|2014-01-29|花王株式会社|Absorbent articles|

---

JP5590834B2|2009-08-11|2014-09-17|ユニ・チャーム株式会社|Nonwoven fabric and method for producing the same|

---

JP2011067484A|2009-09-28|2011-04-07|Kao Corp|Absorbent article|

---

JP5623052B2|2009-09-29|2014-11-12|ユニ・チャーム株式会社|Nonwoven manufacturing method|

---

JP5530693B2|2009-09-30|2014-06-25|大王製紙株式会社|Absorbent articles|

---

JP5222266B2|2009-10-07|2013-06-26|株式会社ホンダアクセス|Floor mat connection structure|

---

JP5421720B2|2009-10-09|2014-02-19|ユニ・チャーム株式会社|Non-woven|

---

JP5395630B2|2009-11-13|2014-01-22|花王株式会社|Absorbent articles|

---

US20110118686A1|2009-11-13|2011-05-19|The Procter & Gamble Company|Substrate with adherence for feces and menses|

---

JP5466489B2|2009-11-16|2014-04-09|花王株式会社|Absorbent articles|

---

JP2011131044A|2009-11-24|2011-07-07|Kao Corp|Absorbent article|

---

JP5551926B2|2009-12-09|2014-07-16|花王株式会社|Absorbent articles|

---

JP5339215B2|2010-03-16|2013-11-13|清水建設株式会社|Indoor damage video display system|

---

JP5506519B2|2010-04-16|2014-05-28|ユニ・チャーム株式会社|A method for easily manufacturing a nonwoven fabric having irregularities, and a method for easily processing a nonwoven fabric|

---

JP5506520B2|2010-04-16|2014-05-28|ユニ・チャーム株式会社|A nonwoven fabric having irregularities, including an extensible fiber and a stretchable fiber, and a method for producing the nonwoven fabric|

---

JP5749907B2|2010-08-31|2015-07-15|ユニ・チャーム株式会社|Absorbent article and sanitary napkin|

---

TWI448277B|2011-03-31|2014-08-11|Uni Charm Corp|Absorbent items|

---

JP6502104B2|2015-01-29|2019-04-17|帝人株式会社|Elastic wire|TWI448277B|2011-03-31|2014-08-11|Uni Charm Corp|Absorbent items|

---

JP5361965B2|2011-04-28|2013-12-04|ユニ・チャーム株式会社|Absorbent articles|

---

JP6092508B2|2011-09-30|2017-03-08|ユニ・チャーム株式会社|Absorbent articles|

---

JP6057664B2|2011-12-28|2017-01-11|ユニ・チャーム株式会社|Absorbent article and manufacturing method thereof|

---

JP5847055B2|2012-02-29|2016-01-20|ユニ・チャーム株式会社|Absorbent articles|

---

JP5717672B2|2012-02-29|2015-05-13|ユニ・チャーム株式会社|Absorbent articles|

---

WO2013129332A1|2012-02-29|2013-09-06|ユニ・チャーム株式会社|Absorbent article|

---

JP5843740B2|2012-02-29|2016-01-13|ユニ・チャーム株式会社|Absorbent articles|

---

US9387135B2|2012-02-29|2016-07-12|Unicharm Corporation|Absorbent article|

---

JP5963639B2|2012-02-29|2016-08-03|ユニ・チャーム株式会社|Absorbent articles|

---

JP5762346B2|2012-03-30|2015-08-12|ユニ・チャーム株式会社|Absorbent articles|

---

JP5726120B2|2012-03-30|2015-05-27|ユニ・チャーム株式会社|Absorbent articles|

---

SG11201405418WA|2012-03-30|2014-11-27|Unicharm Corp|Absorbent and absorbent article provided therewith|

---

JP5726121B2|2012-03-30|2015-05-27|ユニ・チャーム株式会社|Absorbent articles|

---

JP5717686B2|2012-04-02|2015-05-13|ユニ・チャーム株式会社|Absorbent articles|

---

JP5717685B2|2012-04-02|2015-05-13|ユニ・チャーム株式会社|Absorbent articles|

---

JP6116178B2|2012-04-02|2017-04-19|ユニ・チャーム株式会社|Absorbent articles|

---

JP5713951B2|2012-04-02|2015-05-07|ユニ・チャーム株式会社|Absorbent articles|

---

JP6116177B2|2012-09-28|2017-04-19|ユニ・チャーム株式会社|Absorbent articles|

---

JP6057648B2|2012-09-28|2017-01-11|ユニ・チャーム株式会社|Absorbent articles|

---

JP6116179B2|2012-09-28|2017-04-19|ユニ・チャーム株式会社|Absorbent articles|

---

JP6062199B2|2012-09-28|2017-01-18|ユニ・チャーム株式会社|Absorbent articles|

---

JP6202967B2|2013-09-30|2017-09-27|ユニ・チャーム株式会社|Absorbent articles|

---

EP3235945B1|2014-12-17|2021-04-14|Kao Corporation|Liquid film cleavage agent|

---

WO2017104511A1|2015-12-16|2017-06-22|花王株式会社|Non-woven fabric|

---

RU2698821C1|2015-12-16|2019-08-30|Као Корпорейшн|Laminated non-woven material|

---

TWI730105B|2016-05-31|2021-06-11|日商花王股份有限公司|Long fiber non-woven fabric|

---

JP6714435B2|2016-06-03|2020-06-24|花王株式会社|Sanitary absorbent article|

---

JP6669595B2|2016-06-03|2020-03-18|花王株式会社|Absorbent articles|

---

US20180071151A1|2016-09-09|2018-03-15|The Procter & Gamble Company|Systems And Methods Of Applying Compositions To Webs And Webs Thereof|

---

JP6684880B2|2018-10-04|2020-04-22|ユニ・チャーム株式会社|Absorbent article|

---

USD919084S1|2019-03-19|2021-05-11|Johnson & Johnson Consumer Inc.|Absorbent article|

---

USD917692S1|2019-03-19|2021-04-27|Johnson & Johnson Consumer Inc.|Absorbent article|

法律状态:
2018-12-18| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-10-29| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-09-01| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-01-05| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-03-09| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2011-079446|2011-03-31|

---

JP2011079446|2011-03-31|

---

JP2011-192144|2011-09-02|

---

JP2011192144|2011-09-02|

---

PCT/JP2012/058499|WO2012133724A1|2011-03-31|2012-03-23|Absorbent article|

---